Compounds > metformin
Page last updated: 2024-10-30

metformin and Complications of Diabetes Mellitus

metformin has been researched along with Complications of Diabetes Mellitus in 273 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Research Excerpts

ExcerptRelevanceReference
"To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability."9.20Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. ( Ainuddin, JA; Ali, SS; Hasan, AA; Karim, N; Zaheer, S, 2015)
"Metformin using was associated with an increased OS rate and CS rate of colorectal cancer."9.05For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis. ( Chen, Y; Cheng, Y; Liu, C; Shen, L; Tu, F; Xu, J; Zhou, C, 2020)
"Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma."8.95Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. ( Eun, CS; Han, DS; Jung, YS; Park, CH; Park, DI, 2017)
"Metformin is widely used for treating patients with type 2 diabetes mellitus."8.86[New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010)
"The literature dealing with diabetes mellitus, B vitamins and metformin was reviewed."8.81Homocysteine and cardiovascular risk in patients with diabetes mellitus. ( Lavie, L; Levy, Y; Yeromenko, Y, 2001)
"It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib."7.96Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. ( Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY, 2020)
"Background A beneficial effect of metformin on heart failure requires confirmation."7.91Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. ( Tseng, CH, 2019)
"Previous studies have found that metformin can reduce cardiovascular risk, but its association with retinal vein occlusion (RVO) is unknown."7.85Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. ( Chen, SJ; Chiou, SH; Hsu, CC; Hwang, DK; Lin, TC; Peng, CH; Wang, ML, 2017)
"Animal studies showed that the use of metformin after myocardial infarction (MI) resulted in a protective effect on cardiac myocytes."7.81The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction. ( Abualsuod, A; Delongchamp, R; Mehta, JL; Pandat, S; Rutland, JJ; Watts, TE, 2015)
" Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations."7.81Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015)
"We investigated the radiographic and pathologic response rate of esophageal adenocarcinoma treated with neoadjuvant chemoradiation in patients taking metformin."7.79Metformin use and improved response to therapy in esophageal adenocarcinoma. ( Ajani, JA; Cox, JD; Echeverria, AE; Guerrero, TM; Hofstetter, WL; Komaki, R; Lin, SH; McCurdy, MR; Myers, JN; O'Reilly, MS; Sandulache, VC; Skinner, HD; Welsh, JW, 2013)
"This is the first report of drug-induced BP as a group adverse event of the gliptins plus metformin combination therapy for glycaemia control in type 2 diabetes mellitus patients."7.78Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. ( Bassukas, ID; Gaitanis, G; Skandalis, K; Spirova, M; Tsartsarakis, A, 2012)
"To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients."7.78Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. ( Ampuero, J; Bautista, JD; Camacho, I; del Campo, JA; Díaz-Herrero, Mdel M; Figueruela, B; Maraver, M; Nuñez, D; Ranchal, I; Rojas, Á; Romero-Gómez, M, 2012)
"Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction (AMI) in a two meta-analyses of clinical trials."7.75Rosiglitazone and myocardial infarction in patients previously prescribed metformin. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM, 2009)
"We report 4 cases of lactic acidosis in diabetic patients usually treated with metformin."7.72[Metformin-associated lactic acidosis remains a serious complication of metformin therapy]. ( Giunti, C; Grimaud, D; Ichai, C; Levraut, J; Orban, JC, 2003)
"According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure."7.72Metformin and thiazolidinedione use in Medicare patients with heart failure. ( Foody, JM; Havranek, EP; Inzucchi, SE; Krumholz, HM; Masoudi, FA; Setaro, JF; Wang, Y, 2003)
"Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion."7.71Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002)
"Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels."6.78Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. ( Asenjo, S; Cassorla, F; Codner, E; Eyzaguirre, FC; Iñíguez, G; López, P; Mujica, V; Torrealba, I, 2013)
"The heterogeneity of breast cancer, confounded by comorbidity of disease in the elderly population, makes it difficult to determine the actual benefits of metformin therapy."6.52Recent advances in the use of metformin: can treating diabetes prevent breast cancer? ( Hatoum, D; McGowan, EM, 2015)
" This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting."5.62Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. ( Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021)
"Metformin was recently found to increase fetal hemoglobin, which is protective in sickle cell disease (SCD)."5.51Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. ( Badawy, SM; Payne, AB, 2019)
"Metformin treatment had no significant effect on sputum culture conversion (p = 0."5.48The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus. ( Chung, HS; Han, SK; Heo, EY; Kim, DK; Lee, JK; Lee, YJ; Park, JH, 2018)
"This was the first episode of diabetic ketoacidosis (DKA) for this patient."5.46Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. ( Andrews, TJ; Cox, RD; Kolb, J; Parker, C, 2017)
"Metformin treatment itself conferred better OS in comparison within DM patients (HR 0."5.43The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016)
"Metformin-glinides was most cost-effective in the base-case analysis; Metformin-glinides saved $194 USD for one percentage point of reduction in CVD risk, as compared to Metformin-SU."5.43Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. ( Chen, YT; Liu, YM; Ou, HT; Wu, JS, 2016)
"Metformin use was associated with decreased overall mortality (p = 0."5.38The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012)
"To confirm whether type 2 diabetes (T2DM) is an affective disorder (AD) precursor, and to establish possible effects of oral anti-hyperglycemic agents (OAAs)."5.38Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study. ( Chang, HY; Chuang, SY; Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML; Yu, SH, 2012)
"Metformin, however, has the potential to increase serumlactate."5.33[Metformin-associated lactic acidosis in a patient with pre-existing risk factors]. ( Becker, C; Luginbühl, A; Pittl, U; Schlienger, R, 2005)
"To assess the effect of metformin and to compare it with insulin treatment in patients with type 2 diabetes in pregnancy in terms of perinatal outcome, maternal complications, additional insulin requirement, and treatment acceptability."5.20Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy. ( Ainuddin, JA; Ali, SS; Hasan, AA; Karim, N; Zaheer, S, 2015)
"In T2DM patients, pioglitazone was associated with improvement in some measures of left ventricular diastolic function, myocardial glucose uptake, and whole-body insulin sensitivity."5.14Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. ( Bax, JJ; de Jong, HW; de Roos, A; Diamant, M; Heine, RJ; Kamp, O; Lamb, HJ; Lammertsma, AA; Lubberink, M; Paulus, WJ; Rijzewijk, LJ; Romijn, JA; Smit, JW; van der Meer, RW, 2009)
"To determine how glucose control in women with GDM treated with metformin and/or insulin influenced pregnancy outcomes."5.14Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial. ( Gao, W; Hague, WM; McIntyre, HD; Rowan, JA, 2010)
"Metformin using was associated with an increased OS rate and CS rate of colorectal cancer."5.05For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis. ( Chen, Y; Cheng, Y; Liu, C; Shen, L; Tu, F; Xu, J; Zhou, C, 2020)
"Although it is known that metformin can reduce risk of colorectal cancer, it is unclear whether it protects against colorectal adenoma."4.95Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis. ( Eun, CS; Han, DS; Jung, YS; Park, CH; Park, DI, 2017)
" These options are mostly new and have the advantage a neutral or favourable (for GLP-1) effect on body weight in obese type 2 DM patient and the absence of any hypoglycaemic risk in both classes of incretins."4.89[Management of type 2 diabetes: new or previous agents, how to choose?]. ( Halimi, S, 2013)
"Metformin is widely used for treating patients with type 2 diabetes mellitus."4.86[New clinical data with metformin therapy in patients with diabetes mellitus]. ( Jermendy, G, 2010)
"Both metformin and thiazolidinedione derivatives(TZDs) improve insulin resistance, a major pathogenesis of type 2 diabetes, and decrease blood glucose levels without stimulating insulin secretion."4.82[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives]. ( Satoh, J, 2003)
"The literature dealing with diabetes mellitus, B vitamins and metformin was reviewed."4.81Homocysteine and cardiovascular risk in patients with diabetes mellitus. ( Lavie, L; Levy, Y; Yeromenko, Y, 2001)
" On the other hand, treatment of obese patients with metformin significantly reduced the incidence of myocardial infarction and of mortality diabetes related."4.80[Should the occurrence of a first coronary event change the management of diabetes?]. ( Dubois-Laforgue, D; Timsit, J, 2000)
"The paper presents an analysis of clinical symptoms, signs and laboratory data of 330 diabetic patients who developed lactic acidosis after having been treated with biguanides (phenformin, buformin, metformin)."4.75Lactic acidosis in biguanide-treated diabetics: a review of 330 cases. ( Eggstein, M; Luft, D; Schmülling, RM, 1978)
"It remains limited whether diabetes mellitus (DM) and hypertension (HTN) affect the prognosis of advanced hepatocellular carcinoma (HCC) treated with sorafenib."3.96Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib. ( Chuang, PH; Hsieh, MH; Hsieh, TH; Kao, CC; Kao, JT; Kao, TY; Lai, HC; Peng, CY, 2020)
"Background A beneficial effect of metformin on heart failure requires confirmation."3.91Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis. ( Tseng, CH, 2019)
"Previous studies have found that metformin can reduce cardiovascular risk, but its association with retinal vein occlusion (RVO) is unknown."3.85Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study. ( Chen, SJ; Chiou, SH; Hsu, CC; Hwang, DK; Lin, TC; Peng, CH; Wang, ML, 2017)
" Glucose-induced inflammation was partially reversed by metformin."3.81Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency. ( Abrahams, VM; Flannery, CA; Han, CS; Herrin, MA; Mulla, MJ; Pettker, CM; Pitruzzello, MC; Werner, EF, 2015)
"Animal studies showed that the use of metformin after myocardial infarction (MI) resulted in a protective effect on cardiac myocytes."3.81The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction. ( Abualsuod, A; Delongchamp, R; Mehta, JL; Pandat, S; Rutland, JJ; Watts, TE, 2015)
" Interestingly, our findings showed an association of metformin therapy and prolonged progression-free survival in glioblastoma patients with diabetes and therefore serve as a foundation for further preclinical and clinical investigations."3.81Metformin influences progression in diabetic glioblastoma patients. ( Adeberg, S; Ben Harrabi, S; Bernhardt, D; Bostel, T; Debus, J; Diehl, C; Koelsche, C; Mohr, A; Rieken, S, 2015)
"To compare time to acute myocardial infarction (AMI), stroke, or death in a cohort of metformin initiators who added insulin or a sulfonylurea."3.80Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes. ( Elasy, TA; Greevy, RA; Griffin, MR; Grijalva, CG; Hung, AM; Liu, X; Murff, HJ; Roumie, CL, 2014)
"We demonstrate an inhibitory effect of metformin on prevalent and incident goiter."3.79Metformin inhibits goitrogenous effects of type 2 diabetes. ( Derwahl, M; Ittermann, T; Markus, MR; Meisinger, C; Schipf, S; Völzke, H, 2013)
"We investigated the radiographic and pathologic response rate of esophageal adenocarcinoma treated with neoadjuvant chemoradiation in patients taking metformin."3.79Metformin use and improved response to therapy in esophageal adenocarcinoma. ( Ajani, JA; Cox, JD; Echeverria, AE; Guerrero, TM; Hofstetter, WL; Komaki, R; Lin, SH; McCurdy, MR; Myers, JN; O'Reilly, MS; Sandulache, VC; Skinner, HD; Welsh, JW, 2013)
"This is the first report of drug-induced BP as a group adverse event of the gliptins plus metformin combination therapy for glycaemia control in type 2 diabetes mellitus patients."3.78Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. ( Bassukas, ID; Gaitanis, G; Skandalis, K; Spirova, M; Tsartsarakis, A, 2012)
"To investigate the influence of metformin use on liver dysfunction and hepatic encephalopathy in a retrospective cohort of diabetic cirrhotic patients."3.78Metformin inhibits glutaminase activity and protects against hepatic encephalopathy. ( Ampuero, J; Bautista, JD; Camacho, I; del Campo, JA; Díaz-Herrero, Mdel M; Figueruela, B; Maraver, M; Nuñez, D; Ranchal, I; Rojas, Á; Romero-Gómez, M, 2012)
"Higher risks for death (overall and due to cardiovascular disease) and heart failure were found for rosiglitazone compared to pioglitazone."3.77Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data. ( Gallagher, AM; Leufkens, HG; Seabroke, S; Smeeth, L; van Staa, TP, 2011)
"Rosiglitazone was found associated with approximately a 43% increase in risk of acute myocardial infarction (AMI) in a two meta-analyses of clinical trials."3.75Rosiglitazone and myocardial infarction in patients previously prescribed metformin. ( Bassett, K; Carney, G; Dormuth, CR; Maclure, M; Schneeweiss, S; Wright, JM, 2009)
"Baicalin had reduced the hyperglycemia-induced mitochondrial membrane damage, as well as enhanced the effects of metformin, as was observed in the results from the metformin and baicalin treated groups."3.75Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats. ( Hsu, A; Huang, D; Tan, BK; Waisundara, VY, 2009)
"In patients with diabetes mellitus, subclinical LV dysfunction is common and associated with poor diabetic control, advancing age, hypertension and metformin treatment; ACE inhibitor and insulin therapies appear to be protective."3.73Determinants of subclinical diabetic heart disease. ( Downey, M; Fang, ZY; Marwick, TH; Prins, J; Schull-Meade, R, 2005)
"We report 4 cases of lactic acidosis in diabetic patients usually treated with metformin."3.72[Metformin-associated lactic acidosis remains a serious complication of metformin therapy]. ( Giunti, C; Grimaud, D; Ichai, C; Levraut, J; Orban, JC, 2003)
"According to package inserts, metformin is contraindicated in diabetic patients receiving drug treatment for heart failure therapy, and thiazolidinediones are not recommended in diabetic patients with symptoms of advanced heart failure."3.72Metformin and thiazolidinedione use in Medicare patients with heart failure. ( Foody, JM; Havranek, EP; Inzucchi, SE; Krumholz, HM; Masoudi, FA; Setaro, JF; Wang, Y, 2003)
"The aim of the present study was to evaluate the effect of metformin in very obese subjects with acanthosis nigricans."3.71Therapeutic approach in insulin resistance with acanthosis nigricans. ( Dakovska, L; Kirilov, G; Koev, D; Tankova, T, 2002)
"Before metformin therapy, after covariance adjustment for age, the two cohorts did not differ in height, weight, basal metabolic index, insulin, insulin resistance, or insulin secretion."3.71Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. ( Glueck, CJ; Kobayashi, S; Phillips, H; Sieve-Smith, L; Wang, P, 2002)
"85 g metformin daily for 75 days, urinary retention caused by a prostatic adenoma induced functional renal insufficiency and hyperlactacidemia, rapidly reversed with treatment."3.66[Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)]. ( Beaudot, C; Brohon, J; Lavieuville, M; Merceron, RE; Noël, M; Raymond, JP, 1980)
"In participants with type 2 diabetes, the incidences of microvascular complications and death were not materially different among the four treatment groups."3.11Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. ( Bebu, I; Burch, HB; Buse, JB; Cherrington, AL; Fortmann, SP; Green, JB; Kahn, SE; Kirkman, MS; Krause-Steinrauf, H; Lachin, JM; Larkin, ME; Nathan, DM; Phillips, LS; Pop-Busui, R; Steffes, M; Tiktin, M; Tripputi, M; Wexler, DJ; Younes, N, 2022)
"Metformin use was associated with decreased fracture risk (HR = 0."2.90Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus. ( Adler, RA; Colón-Emeric, C; LaFleur, J; Lee, RH; Lyles, KW; Pieper, C; Sloane, R; Van Houtven, C, 2019)
"Patients with type 2 diabetes are at risk of microvascular and macrovascular complications."2.87Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial. ( Cho, HC; Kim, NH; Kim, SG; Kwak, SH; Lee, J; Lee, YH; Lim, S; Moon, JS; Moon, MK, 2018)
"The dapagliflozin treatment arm was associated with a mean incremental benefit of 0."2.80The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. ( Bergenheim, K; Callan, L; Charokopou, M; Lister, S; McEwan, P; Postema, R; Roudaut, M; Tolley, K; Townsend, R, 2015)
"Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels."2.78Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus. ( Asenjo, S; Cassorla, F; Codner, E; Eyzaguirre, FC; Iñíguez, G; López, P; Mujica, V; Torrealba, I, 2013)
" GH dosage was increased from 0."2.72Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review. ( Fujisawa, Y; Fukami, M; Inoue, T; Kagami, M; Masunaga, Y; Muramatsu, M; Ogata, T; Ono, H; Saitsu, H, 2021)
"Metformin is an anti-hyperglycemic agent with host-directed immune-modulatory effects, which relieve exaggerated inflammation and reduce lung tissue damage."2.72The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review. ( Hajikhani, B; Mirsaeidi, M; Nasiri, MJ; Nejadghaderi, SA; Zahmatkesh, MM; Zangiabadian, M, 2021)
"Metformin was extensively studied for its antioxidant, anti-inflammatory, immunomodulatory, and antiviral capabilities that would explain its ability to confer cardiopulmonary and vascular protection in COVID-19."2.72Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing. ( Büsselberg, D; Kubatka, P; Liskova, A; Samuel, SM; Varghese, E, 2021)
"Obesity is one of the main risk factors for type 2 diabetes (T2D), representing a major worldwide health crisis."2.61Body Weight Considerations in the Management of Type 2 Diabetes. ( Apovian, CM; O'Neil, PM; Okemah, J, 2019)
"Dapagliflozin treatment was more cost-effective compared with metformin treatment for Chinese type 2 diabetes patients."2.61Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes. ( Cai, X; Chen, Y; Gu, S; Ji, L; Nie, L; Shi, L; Yang, W, 2019)
"The global epidemic of type 2 diabetes has prompted numerous studies and public health efforts to reduce its development."2.61Does diabetes prevention translate into reduced long-term vascular complications of diabetes? ( Bennett, PH; Crandall, JP; Edelstein, SL; Goldberg, RB; Kahn, SE; Knowler, WC; Mather, KJ; Mudaliar, S; Nathan, DM; Orchard, TJ; Temprosa, M; White, NH, 2019)
"Metformin has also been reported to decrease expression of multiple histone methyltransferases, to increase the activity of the class III HDAC SIRT1 and to decrease the influence of DNMT inhibitors."2.58Epigenetic effects of metformin: From molecular mechanisms to clinical implications. ( Bridgeman, SC; Ellison, GC; Mamotte, CDS; Melton, PE; Newsholme, P, 2018)
"Metformin has garnered more interest as a chemo-preventive agent given the increased liver cancer risk in diabetic patients."2.55Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients. ( Ma, S; Tan, H; Xiao, Y; Zheng, Y; Zhou, P, 2017)
"Diabetes mellitus is associated with an elevation in gynecologic cancer risk."2.53Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives. ( Alexandrou, A; Botsis, D; Creatsas, G; Grigoriadis, C; Iavazzo, C; Iliodromiti, Z; Sifakis, S; Siristatidis, C; Vrachnis, N, 2016)
"The substantial burden of cancer and diabetes and the association between the two conditions has been a motivation for researchers to look for targeted strategies that can simultaneously affect both diseases and reduce their overlapping burden."2.53Does Metformin Reduce Cancer Risks? Methodologic Considerations. ( Golozar, A; Lin, JA; Liu, S; Peairs, K; Yeh, HC, 2016)
"Iatrogenic and compensatory hyperinsulinemia are metabolic disruptors of β-cells, liver, muscle, kidney, brain, heart and vasculature, inflammation, and lipid homeostasis, among other systems."2.53Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile. ( Herman, ME; Jellinger, PS; Schwartz, SS, 2016)
"The heterogeneity of breast cancer, confounded by comorbidity of disease in the elderly population, makes it difficult to determine the actual benefits of metformin therapy."2.52Recent advances in the use of metformin: can treating diabetes prevent breast cancer? ( Hatoum, D; McGowan, EM, 2015)
"Diabetes may increase the risk of gastric cancer through shared risk factors including obesity, insulin resistance, hyperinsulinemia and smoking."2.50Diabetes and gastric cancer: the potential links. ( Tseng, CH; Tseng, FH, 2014)
"Diabetic complications are major health problems worldwide, with the cost of caring for diabetes rising to US$245 billion in 2012 in the U."2.50Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications. ( Beisswenger, PJ, 2014)
"Although a correlation between pancreatic cancer and diabetes mellitus has long been suspected, the potential role diabetes mellitus plays in the pathogenicity of both hepatocellular carcinoma and colon cancer is becoming increasingly well defined."2.50Diabetes mellitus as a novel risk factor for gastrointestinal malignancies. ( Herrigel, DJ; Moss, RA, 2014)
"Long-standing type 1 diabetes and type 2 diabetes increase the risk for this malignancy, but the cancer can also induce pancreatogenic, or type 3c, diabetes as well."2.49Diabetes and cancer: placing the association in perspective. ( Andersen, DK, 2013)
"Metformin was not associated with the risk of: breast cancer, lung cancer, ovarian cancer, uterus cancer, prostate cancer, bladder cancer, kidney cancer, and melanoma."2.49Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. ( Franciosi, M; Lapice, E; Lucisano, G; Nicolucci, A; Pellegrini, F; Strippoli, GF, 2013)
"Metformin treatment was potentially protective."2.48Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis. ( Cao, W; Kang, D; Liu, Z; Wang, P; Wang, Y, 2012)
"We examined cancer outcomes and all-cause mortality in published randomised controlled trials (RCTs)."2.48Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. ( Ali, R; Bankhead, CR; Bethel, MA; Cairns, BJ; Camisasca, RP; Crowe, FL; Farmer, AJ; Harrison, S; Hirst, JA; Holman, RR; Home, P; Kahn, SE; McLellan, JH; Perera, R; Plüddemann, A; Ramachandran, A; Roberts, NW; Rose, PW; Schweizer, A; Stevens, RJ; Viberti, G, 2012)
"Type 3 diabetes mellitus is an effect, and therefore a harbinger, of pancreatic cancer in at least 30% of patients."2.47Diabetes and pancreatic cancer: chicken or egg? ( Andersen, DK; Elahi, D; Magruder, JT, 2011)
"Patients with type 2 diabetes often have multiple cardiovascular risk factors and require multiple cardiac and diabetes medications."2.47Clinical practice and implications of recent diabetes trials. ( Webster, MW, 2011)
"In the pathophysiology of type 2 diabetes there are several biological processes, which may explain the higher cancer risk in type 2 diabetes."2.47[Diabetes and cancer risk: oncologic considerations]. ( Rosta, A, 2011)
"Type 2 diabetes is associated with increased risk of breast, colon, pancreatic and other types of cancer, while type 1 diabetes is associated with increase in stomach, pancreatic, endometrial and cervical cancer."2.47Diabetes mellitus and the risk of cancer. ( Abdallah, M; Alickaj, A; Asad, S; Forte, V; Mahmud, S; McFarlane, SI; Pandey, A, 2011)
"Metformin has recently gained much attention as it appears to reduce cancer incidence and improve prognosis of patients with diabetes."2.47Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. ( Gallagher, EJ; LeRoith, D, 2011)
"Diabetes and cancer are common conditions, and their co-diagnosis in the same individual is not infrequent."2.46Diabetes and cancer. ( Chowdhury, TA, 2010)
"Metformin is a potent antihyperglycemic agent widely used in the management of type 2 diabetes whose main actions are the suppression of gluconeogenesis and the improvement of glucose uptake and insulin sensitivity."2.44Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview. ( Carvalho, C; Correia, S; Moreira, PI; Oliveira, CR; Santos, MS; Seiça, R, 2008)
"Obesity is not necessary to observe insulin resistance in humans since severe insulin resistance also characterizes patients lacking subcutaneous fat such as those with HAART (highly-active antiretroviral therapy) - associated lipodystrophy."2.43The fatty liver and insulin resistance. ( Westerbacka, J; Yki-Järvinen, H, 2005)
"Treatment with rosiglitazone in combination with metformin provides better glycaemic control over the remaining lifetime of patients than metformin and sulfonylurea combination therapy."2.43Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK. ( Bagust, A; Beale, S; Hulme, L; Martin, A; Shearer, AT, 2006)
"To assess the lifetime diabetes health consequences and cost-effectiveness in Spain of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in overweight and obese patients failing to maintain glycaemic control with metformin monotherapy compared with conventional care of metformin in combination with either sulfonylureas or bedtime insulin."2.43Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain. ( Ampudia-Blasco, FJ; Bagust, A; Martínez-Lage Alvarez, B; París, G; Pérez Escolano, I; Shearer, AT, 2006)
"Only metformin has clearly proved that it can reduce mortality in obese patients with type 2 diabetes."2.42[Drug treatment of type 2 diabetes]. ( Bock, GM; Plank, J, 2003)
"Diabetes mellitus is associated with alterations in a number of key metabolic pathways."2.40Drug administration in patients with diabetes mellitus. Safety considerations. ( Cooper, ME; Gilbert, RE; Krum, H, 1998)
"Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide, being available."1.91Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy. ( Bain, S; Berry, S; Hunt, B; Malkin, SJP; Ren, H, 2023)
"Metformin use was associated with a lower risk of rotator cuff disease in patients with type 2 DM."1.72Metformin use is associated with a lower risk of rotator cuff disease in patients with Type 2 diabetes mellitus. ( Chang, R; Chou, MC; Huang, JY; Hung, YM; Tu, TY; Wei, JC, 2022)
"To evaluate the impact of type 2 diabetes (T2D) and obesity on COVID-19 severity, we conducted a cohort study with 28,095 anonymized COVID-19 patients using data from the COVID-19 Research Database from January 1, 2020 to November 30, 2020."1.62Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States. ( Ando, W; Atsuda, K; Hanaki, H; Horii, T; Otori, K; Uematsu, T, 2021)
" This study is designed to explore the therapeutic potential of metformin and montelukast, in combination with Lactobacillus, for modulation of intestinal flora and suppression of oxidative stress in testicular and liver damage in diabetic male rats."1.62The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress. ( El-Baz, AM; El-Sokkary, MMA; Hassan, HM; Khodir, AE; Shata, A, 2021)
"The prevalence of type 2 diabetes in youth is increasing, but little is known regarding the occurrence of related complications as these youths transition to adulthood."1.62Long-Term Complications in Youth-Onset Type 2 Diabetes. ( Bjornstad, P; Caprio, S; Drews, KL; Gubitosi-Klug, R; Nathan, DM; Tesfaldet, B; Tryggestad, J; White, NH; Zeitler, P, 2021)
" This study aimed to explore the real-world use of anti-diabetic agent metformin in combination with pemetrexed-based platinum doublets in a first-line setting."1.62Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes. ( Chang, GR; Chen, CM; Chen, W; Chong, KY; Cidem, A; Lin, CH; Staniczek, T; Tsai, YT; Wang, JL; Yen, CC, 2021)
"Although the survival rate of stomach cancer has improved, the disease burden is still high."1.56Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database. ( Bae, YJ; Choi, EA; Hyun, HJ; Kang, HT; Kim, J; Kim, Y, 2020)
"Metformin was recently found to increase fetal hemoglobin, which is protective in sickle cell disease (SCD)."1.51Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus. ( Badawy, SM; Payne, AB, 2019)
"Metformin is a promising drug for cancer prevention and treatment, especially in the diabetic population."1.4814-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma. ( Chen, Y; Cheng, K; Ding, J; Du, Y; Li, ZK; Liu, JQ; Liu, JY; Qiu, M; Tang, J; Wang, YY; Yang, L; Zhang, YN; Zhu, YT, 2018)
"Metformin treatment had no significant effect on sputum culture conversion (p = 0."1.48The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus. ( Chung, HS; Han, SK; Heo, EY; Kim, DK; Lee, JK; Lee, YJ; Park, JH, 2018)
"Metformin use was associated positively with high-aggressive prostate cancer in Blacks (OR 2."1.48The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study. ( Bensen, JT; Cai, J; Drake, BF; Farnan, L; Fontham, ETH; Khan, S; Mohler, JL; Nielsen, ME; Olshan, AF; Troester, MA, 2018)
"Type 2 diabetes mellitus is a common disease, affecting up to 13."1.46[Vitamin B12 Deficiency in Type 2 Diabetes Mellitus]. ( Azinheira, J; Capitão, RM; Sequeira Duarte, J; Tavares Bello, C; Vasconcelos, C, 2017)
"This was the first episode of diabetic ketoacidosis (DKA) for this patient."1.46Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. ( Andrews, TJ; Cox, RD; Kolb, J; Parker, C, 2017)
" These results suggest that metformin administration reversed the adverse effects of diabetes on orthodontic tooth movement."1.46Histological evidence that metformin reverses the adverse effects of diabetes on orthodontic tooth movement in rats. ( Amizuka, N; Du, J; Feng, W; Guo, J; Li, M; Liu, H; Lu, B; Sun, J, 2017)
"Metformin has been shown to improve the survival of patients with breast, lung and endometrial cancer receiving chemotherapy, and enhance chemotherapeutic efficacy in breast cancer and colon cancer cells."1.46The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer. ( Klotz, LH; Mayer, MJ; Venkateswaran, V, 2017)
" The secondary analysis evaluated the effect of dosage using a principal components analysis."1.46Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System. ( Albert, AY; Gill, S; Hutcheon, JA; Kwon, JS, 2017)
"Metformin has recently received attention as a potential anticancer treatment."1.43Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. ( An, JY; Cheong, JH; Chung, HC; Heo, SJ; Hyung, WJ; Jeong, YH; Jung, I; Jung, M; Kim, HI; Kim, HS; Lee, CK; Noh, SH; Rha, SY, 2016)
"Metformin treatment itself conferred better OS in comparison within DM patients (HR 0."1.43The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy. ( Bang, YJ; Choi, Y; Han, SW; Im, SA; Kim, TY; Lee, KH; Oh, DY, 2016)
"A total of 543 rectal cancer patients who were treated with neoadjuvant chemoradiotherapy followed by radical surgery from January 2007 to December 2011 were reviewed."1.43Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer. ( Cho, YB; Choi, DH; Huh, JW; Kim, HC; Lee, WY; Oh, BY; Park, HC; Park, YA; Park, YS; Yun, SH, 2016)
"Metformin-glinides was most cost-effective in the base-case analysis; Metformin-glinides saved $194 USD for one percentage point of reduction in CVD risk, as compared to Metformin-SU."1.43Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan. ( Chen, YT; Liu, YM; Ou, HT; Wu, JS, 2016)
"Data on risk factors for Clostridium difficile infection (CDI) in diabetic patients are scarce."1.42Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study. ( Barsheshet, A; Bishara, J; Eliakim-Raz, N; Fishman, G; Goldberg, E; Stein, GY; Yahav, D; Zvi, HB, 2015)
"Metabolic syndrome has been associated with nodular goiter."1.42Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome. ( Barreto, A; Blanc, E; Brenta, G; Brodschi, D; Cejas, C; Faingold, C; Fossati, P; Musso, C; Nepote, A; Ponce, C; Salgado, P; Schnitman, M, 2015)
"Metformin was treated as a time-dependent variable; and of these patients, 286,106 were never-users, and 193,369 were ever-users."1.42Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. ( Tseng, CH, 2015)
"A model that incorporates HbA1c and diabetes complications can serve as a useful clinical decision tool for selection of treatment options."1.40Second-line agents for glycemic control for type 2 diabetes: are newer agents better? ( Denton, BT; Mason, JE; McCoy, RG; Shah, ND; Smith, SA; Zhang, Y, 2014)
"Metformin is a target therapy that increases median overall survival but is not a radiation sensitizer in patients with pancreatic cancer who present with diabetes."1.40Diabetes and pancreatic cancer. ( De Souza, AL; Saif, MW, 2014)
"Treatment with metformin plus vildagliptin yielded a mean per-patient gain of 0."1.40Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective. ( Calado, F; Carvalho, D; Gruenberger, JB; Johal, S; Ong, SH; Silva-Nunes, J; Viana, R; Viriato, D, 2014)
"Metformin treatment was effective in lowering hyperglycemia only during the first 2 weeks of treatment."1.40Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. ( Boivin, GP; Elased, KM; Somineni, HK, 2014)
"The treatment for patients with type 2 diabetes mellitus (T2DM) follows a stepwise progression."1.40The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus. ( Curtis, BH; Gahn, JC; Murphy, DR; Smolen, HJ; Yu, X, 2014)
"Metformin was treated as a time-dependent variable."1.40Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus. ( Tseng, CH, 2014)
"In the families of cancer-free DM2 women, DM2 was found to be significantly more frequent (30."1.38Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin. ( Berstein, LM; Boyarkina, MP; Teslenko, SY, 2012)
"Metformin use was associated with decreased overall mortality (p = 0."1.38The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. ( Cheon, JH; Hong, SP; Jeon, SM; Kim, TI; Kim, WH; Lee, JH, 2012)
"Metformin use was significantly associated with longer survival in patients with nonmetastatic disease only."1.38Metformin use is associated with better survival of diabetic patients with pancreatic cancer. ( Abbruzzese, JL; Hassan, M; Li, D; Sadeghi, N; Yeung, SC, 2012)
"To confirm whether type 2 diabetes (T2DM) is an affective disorder (AD) precursor, and to establish possible effects of oral anti-hyperglycemic agents (OAAs)."1.38Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study. ( Chang, HY; Chuang, SY; Hsu, CC; Lee, MS; Tsai, HN; Wahlqvist, ML; Yu, SH, 2012)
"non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes are associated with dyslipidaemia, inflammation and oxidative stress."1.37Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia. ( Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R, 2011)
"Patients with type 2 diabetes are at an increased risk for disease and treatment related complications after the initial approach of oral mono/dual antidiabetic therapy has failed."1.36Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline. ( Binz, C; Bramlage, P; Deeg, E; Gitt, AK; Krekler, M; Plate, T; Tschöpe, D, 2010)
"The prevalence of type 2 diabetes in Thailand is 9."1.36Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death. ( Benjasuratwong, Y; Bunnag, P; Chetthakul, T; Deerochanawong, C; Komoltri, C; Kosachunhanun, N; Krittiyawong, S; Leelawatana, R; Mongkolsomlit, S; Ngarmukos, C; Plengvidhya, N; Pratipanawatr, T; Rawdaree, P; Suwanwalaikorn, S, 2010)
"Overt type 2 diabetes is usually preceded by a condition known as prediabetes, which is characterized by impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)."1.35Identification and treatment of prediabetes to prevent progression to type 2 diabetes. ( Fonseca, VA, 2008)
"Over half of these German patients with type 2 diabetes failed to attain the HbA(1c) target for glycemic control."1.34Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. ( Lage, MJ; Secnik, K; Yurgin, N, 2007)
"Five patients with type 2 diabetes, three of them treated with insulin and two with oral antidiabetic drugs, receiving imatinib due to chronic myeolid leukaemia are reported."1.34[No influence of imatinib on type 2 diabetes]. ( Chodorowski, Z; Hellmann, A; Prejzner, W; Sein Anand, J, 2007)
"Metformin, however, has the potential to increase serumlactate."1.33[Metformin-associated lactic acidosis in a patient with pre-existing risk factors]. ( Becker, C; Luginbühl, A; Pittl, U; Schlienger, R, 2005)
"Type 2 diabetes mellitus is a heterogeneous condition in which the clinical manifestation of hyperglycemia is a reflection of the impaired balance between insulin sensitivity and insulin secretion."1.33Type 2 diabetes mellitus in youth: the complete picture to date. ( Arslanian, S; Bacha, F; Gungor, N; Hannon, T; Libman, I, 2005)
"Patients with type 2 diabetes and complete HbA(1c) (A1C) data and treated with metformin or sulfonylurea monotherapy for at least three visits before receiving dual oral therapy were included (n = 644)."1.33Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes. ( Constantino, MI; Molyneaux, LM; Ong, CR; Twigg, SM; Yue, DK, 2006)
"Hirsutism is the manifestation of hyperandrogenemia in PCOS."1.32The treatment of polycystic ovary syndrome. ( Ajossa, S; Guerriero, S; Melis, GB; Orrù, M; Paoletti, AM, 2004)
"Of these patients 16 had untreated hypertension and 28 had diabetic complications, which ranged from microaneurysms to renal failure and blindness."1.26Plasma renin activity in diabetes mellitus. ( Burden, AC; Thurston, H, 1979)

Research

Studies (273)

TimeframeStudies, this research(%)All Research%
pre-199013 (4.76)18.7374
1990's5 (1.83)18.2507
2000's66 (24.18)29.6817
2010's160 (58.61)24.3611
2020's29 (10.62)2.80

Authors

AuthorsStudies
Ando, W1
Horii, T1
Uematsu, T1
Hanaki, H1
Atsuda, K1
Otori, K1
Ding, Y2
Zhou, Y2
Ling, P1
Feng, X3
Luo, S1
Zheng, X1
Little, PJ2
Xu, S2
Weng, J2
Chang, R1
Tu, TY1
Hung, YM1
Huang, JY1
Chou, MC1
Wei, JC1
Nathan, DM3
Lachin, JM1
Bebu, I1
Burch, HB1
Buse, JB1
Cherrington, AL1
Fortmann, SP1
Green, JB1
Kahn, SE3
Kirkman, MS1
Krause-Steinrauf, H1
Larkin, ME1
Phillips, LS1
Pop-Busui, R1
Steffes, M1
Tiktin, M1
Tripputi, M1
Wexler, DJ1
Younes, N1
Ren, H1
Berry, S2
Malkin, SJP1
Hunt, B2
Bain, S1
Tseng, CH4
Badawy, SM1
Payne, AB1
Dludla, PV1
Silvestri, S1
Orlando, P1
Gabuza, KB1
Mazibuko-Mbeje, SE1
Nyambuya, TM1
Mxinwa, V1
Mokgalaboni, K1
Johnson, R1
Muller, CJF1
Tiano, L1
Louw, J1
Nkambule, BB1
Gabriel, R1
Boukichou Abdelkader, N1
Acosta, T1
Gilis-Januszewska, A1
Gómez-Huelgas, R1
Makrilakis, K1
Kamenov, Z1
Paulweber, B1
Satman, I1
Djordjevic, P1
Alkandari, A1
Mitrakou, A1
Lalic, N1
Colagiuri, S1
Lindström, J1
Egido, J1
Natali, A1
Pastor, JC1
Teuschl, Y1
Lind, M1
Silva, L1
López-Ridaura, R1
Tuomilehto, J1
Terasaki, F1
Sugiura, T1
Okamura, Y1
Ito, T1
Yamamoto, Y1
Ashida, R1
Ohgi, K2
Uesaka, K1
Kim, J1
Hyun, HJ1
Choi, EA1
Kim, Y4
Bae, YJ1
Kang, HT1
Zhou, X3
Wang, Q4
Nie, L2
Zhang, P2
Zhao, P1
Yuan, Q1
Ji, N1
Fung, EB1
Ahmad, T1
Killilea, DW1
Hussain, R1
Lal, A1
Chee, YJ1
Tan, SK1
Yeoh, E1
Kyo, S1
Nakayama, K1
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Li, H4
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Li, X11
Henson, MA1
Unsihuay, D1
Qiu, J2
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y2
Neradilek, MB1
Wu, XT1
Zhang, D2
Huang, W1
Cui, Y2
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X1
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X2
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, Y6
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J5
Zhang, E1
Zhang, J3
Li, Y6
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y5
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A2
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X2
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F2
Wang, YS1
Wang, C3
Wang, W1
Wang, S2
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Wang, L1
Zhu, J2
Zhang, L2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X7
Lee, DF1
Shen, J4
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y5
Wu, X1
Lu, J2
Li, M2
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S2
Zhang, M4
Zhang, H1
Yang, T2
Dong, Y1
Xu, Y1
Yuan, Z1
Cao, J1
Zheng, Y2
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z3
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J3
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Rathore, MG1
Reddy, K1
Chen, H1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C4
Gao, F1
Qi, Y1
Lu, H1
Zhang, X8
Cai, X3
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Chen, S2
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W4
Hu, X1
Zhang, F2
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I2
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J1
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A2
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T2
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M1
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D4
Tan, H2
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W2
Ma, S2
Lin, W1
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X1
Jiang, F1
Yuan, D1
Chen, Q1
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD2
Lang, CC2
Wang, XW1
Yuan, LJ1
Yang, Y2
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H2
He, Z1
Chen, B2
Wu, J1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X1
Duong, F1
Kong, W1
Chang, JH1
Sun, J2
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y1
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J2
Shao, Z1
Yuan, C1
Wu, Y1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T1
Li, Q1
Cao, T1
Guo, L1
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S2
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P1
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J2
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Masunaga, Y1
Fujisawa, Y1
Muramatsu, M1
Ono, H1
Fukami, M1
Kagami, M1
Saitsu, H1
Ogata, T1
Goldberg, H1
Mohsin, FK1
Berlin, A1
Chandrasekar, T1
Wallis, CJD1
Klaassen, Z1
Ahmad, AE1
Saskin, R1
Kenk, M1
Saarela, O1
Kulkarni, GS1
Alibhai, SMH1
Fleshner, N1
Nahar, N1
Mohamed, S1
Mustapha, NM1
Lau, S1
Ishak, NIM1
Umran, NS1
Ahn, HK1
Lee, YH2
Koo, KC1
Shestakova, MV1
Vikulova, OK1
Isakov, MА1
Dedov, II1
Hsieh, MH1
Kao, TY1
Hsieh, TH1
Kao, CC1
Peng, CY1
Lai, HC2
Chuang, PH1
Kao, JT1
Zangiabadian, M1
Nejadghaderi, SA1
Zahmatkesh, MM1
Hajikhani, B1
Mirsaeidi, M1
Nasiri, MJ1
Lian, J1
Fu, J1
El-Baz, AM1
Shata, A1
Hassan, HM1
El-Sokkary, MMA1
Khodir, AE1
Varghese, E1
Samuel, SM1
Liskova, A1
Kubatka, P1
Büsselberg, D1
Ni, X1
Tang, L1
Jacobi, O1
Landman, Y1
Reinhorn, D1
Icht, O1
Sternschuss, M1
Rotem, O1
Finkel, I1
Allen, AM1
Dudnik, E1
Goldstein, DA1
Zer, A1
Bjornstad, P1
Drews, KL1
Caprio, S1
Gubitosi-Klug, R1
Tesfaldet, B1
Tryggestad, J1
White, NH2
Zeitler, P1
Wang, JL1
Tsai, YT1
Lin, CH2
Cidem, A1
Staniczek, T1
Chang, GR1
Yen, CC1
Chong, KY1
Chen, CM1
Jung, YS1
Park, CH1
Eun, CS1
Park, DI1
Han, DS1
Skolnik, N1
Jaffa, FM1
Kalyani, RR1
Johnson, E1
Shubrook, JH2
Raslan, IA1
McDonald, EG1
Lee, TC1
Xiao, Y1
Zhou, P1
Kragh, N1
McConnachie, CC1
Valentine, WJ3
Rossi, MC1
Montagnoli, R1
Riediger, ND1
Lukianchuk, V1
Roulette, J1
Lix, LM1
Elliott, L1
Bruce, SG1
Gillani, SW1
Sulaiman, SAS1
Abdul, MIM1
Baig, MR1
Kosi-Trebotic, L1
Thomas, A1
Harreiter, J1
Chmelik, M1
Trattnig, S1
Kautzky-Willer, A1
Han, X1
Tao, Y1
Deng, Y1
Yu, J1
Jiang, G1
Bauduceau, B1
Le Floch, JP1
Halimi, S2
Verny, C1
Doucet, J1
Lin, TC1
Hwang, DK1
Hsu, CC2
Peng, CH1
Wang, ML1
Chiou, SH1
Chen, SJ1
Szwergold, B1
Fixen, CW1
Fixen, DR1
Tavares Bello, C1
Capitão, RM1
Sequeira Duarte, J1
Azinheira, J1
Vasconcelos, C1
Gupta, G1
de Jesus Andreoli Pinto, T1
Chellappan, DK1
Mishra, A1
Malipeddi, H1
Dua, K1
Ding, J1
Zhu, YT1
Yang, L1
Tang, J1
Wang, YY1
Cheng, K1
Liu, JQ1
Zhang, YN1
Li, ZK1
Du, Y1
Qiu, M1
Liu, JY1
Bridgeman, SC1
Ellison, GC1
Melton, PE1
Newsholme, P1
Mamotte, CDS1
Lee, YJ1
Han, SK1
Park, JH1
Lee, JK1
Kim, DK1
Chung, HS1
Heo, EY1
Kumar, NP1
Moideen, K1
Viswanathan, V1
Shruthi, BS1
Sivakumar, S1
Menon, PA1
Kornfeld, H1
Babu, S1
Kim, NH1
Lim, S1
Kwak, SH1
Moon, MK1
Moon, JS1
Cho, HC1
Lee, J1
Kim, SG1
Khan, S1
Cai, J1
Nielsen, ME1
Troester, MA1
Mohler, JL1
Fontham, ETH1
Farnan, L1
Drake, BF1
Olshan, AF1
Bensen, JT1
Apovian, CM1
Okemah, J1
O'Neil, PM1
Carris, NW1
Magness, RR1
Labovitz, AJ1
Pawaskar, M1
Bilir, SP1
Kowal, S1
Gonzalez, C1
Rajpathak, S2
Davies, G1
Shi, L1
Yang, W1
Ji, L1
Jiao, Y1
Xing, Y1
Gao, P1
Xu, J2
Liu, M1
Yu, M1
Zhou, J1
Zhang, W1
Lee, RH1
Sloane, R1
Pieper, C1
Lyles, KW1
Adler, RA1
Van Houtven, C1
LaFleur, J1
Colón-Emeric, C1
Bennett, PH1
Crandall, JP1
Edelstein, SL1
Goldberg, RB2
Knowler, WC1
Mather, KJ1
Mudaliar, S1
Orchard, TJ2
Temprosa, M2
Cheng, Y1
Zhou, C1
Shen, L1
Tu, F1
Andersen, DK3
Ramkumar, S1
Tandon, N1
Ittermann, T1
Markus, MR1
Schipf, S1
Derwahl, M1
Meisinger, C1
Völzke, H1
Antonopoulou, M1
Bahtiyar, G1
Banerji, MA1
Sacerdote, AS1
Noto, H1
Goto, A1
Tsujimoto, T1
Noda, M1
Franciosi, M1
Lucisano, G1
Lapice, E1
Strippoli, GF1
Pellegrini, F1
Nicolucci, A2
Kajbaf, F1
Arnouts, P1
de Broe, M1
Lalau, JD3
Chen, TY1
Qin, S1
Duan, Y1
Wang, G1
Vestergaard, P1
Codner, E1
Iñíguez, G1
López, P1
Mujica, V1
Eyzaguirre, FC1
Asenjo, S1
Torrealba, I1
Cassorla, F1
Alagiakrishnan, K1
Sankaralingam, S1
Ghosh, M1
Mereu, L1
Senior, P1
Hayashi, T1
Kotani, H1
Yamaguchi, T1
Taguchi, K1
Iida, M1
Ina, K1
Maeda, M1
Kuzuya, M1
Hattori, Y1
Ignarro, LJ1
Zhang, ZJ1
Reddi, A1
Powers, MA1
Dellavalle, RP1
Lee, CH1
Hsieh, MJ1
Chang, SH1
Lin, YH1
Liu, SJ1
Lin, TY1
Hung, KC1
Pang, JH1
Juang, JH1
McCoy, RG1
Mason, JE1
Smith, SA1
Shah, ND1
Denton, BT1
Tseng, FH1
De Souza, AL1
Saif, MW1
Beisswenger, PJ1
Viriato, D1
Calado, F1
Gruenberger, JB1
Ong, SH1
Carvalho, D1
Silva-Nunes, J1
Johal, S1
Viana, R1
Somineni, HK1
Boivin, GP1
Elased, KM1
Harmsen, WS2
Mettler, TA2
Kim, WR2
Roberts, RO3
Therneau, TM2
Roberts, LR3
Chaiteerakij, R3
Roumie, CL1
Greevy, RA1
Grijalva, CG1
Hung, AM1
Murff, HJ1
Elasy, TA1
Griffin, MR1
Sánchez, H1
Masferrer, D1
Lera, L1
Arancibia, E1
Angel, B1
Albala, C1
Aldam, P1
Levy, N1
Hall, GM2
Hu, Y1
Ley, SH1
Hu, FB1
Smolen, HJ1
Murphy, DR1
Gahn, JC1
Yu, X2
Curtis, BH1
Balasubramanyam, M1
Han, CS1
Herrin, MA1
Pitruzzello, MC1
Mulla, MJ1
Werner, EF1
Pettker, CM1
Flannery, CA1
Abrahams, VM1
Danzig, MR1
Kotamarti, S1
Ghandour, RA1
Rothberg, MB1
Dubow, BP1
Benson, MC1
Badani, KK1
McKiernan, JM1
Herrigel, DJ1
Moss, RA1
Lee, CK1
Jung, M1
Heo, SJ1
Jeong, YH1
An, JY1
Kim, HI1
Cheong, JH1
Hyung, WJ1
Noh, SH1
Kim, HS1
Rha, SY1
Chung, HC1
Eliakim-Raz, N1
Fishman, G1
Yahav, D1
Goldberg, E1
Stein, GY1
Zvi, HB1
Barsheshet, A1
Bishara, J1
Deng, D1
Skrip, L1
Choi, Y1
Kim, TY2
Oh, DY1
Lee, KH1
Han, SW1
Im, SA1
Bang, YJ1
Blanc, E1
Ponce, C1
Brodschi, D1
Nepote, A1
Barreto, A1
Schnitman, M1
Fossati, P1
Salgado, P1
Cejas, C1
Faingold, C1
Musso, C1
Brenta, G1
Charokopou, M1
McEwan, P1
Lister, S1
Callan, L1
Bergenheim, K1
Tolley, K1
Postema, R1
Townsend, R1
Roudaut, M1
Yang, Z1
Wang, MM1
Lin, S1
Chen, YM1
Shu, J1
Lu, HY1
Zhang, YJ1
Xie, RY1
Zeng, LY1
Mu, PW1
Hatoum, D1
McGowan, EM1
Ainuddin, JA1
Karim, N1
Zaheer, S1
Ali, SS1
Hasan, AA1
Zhang, JW1
Sun, Q1
Abualsuod, A2
Rutland, JJ1
Watts, TE1
Pandat, S1
Delongchamp, R1
Mehta, JL1
Krul-Poel, YH1
Agca, R1
Lips, P1
van Wijland, H1
Stam, F1
Simsek, S1
Zanders, MM1
van Herk-Sukel, MP1
Vissers, PA1
Herings, RM1
Haak, HR1
van de Poll-Franse, LV1
Fath, R1
Eyuboglu, M1
Adeberg, S1
Bernhardt, D1
Ben Harrabi, S1
Bostel, T1
Mohr, A1
Koelsche, C1
Diehl, C1
Rieken, S1
Debus, J1
Vrachnis, N1
Iavazzo, C1
Iliodromiti, Z1
Sifakis, S1
Alexandrou, A1
Siristatidis, C1
Grigoriadis, C1
Botsis, D1
Creatsas, G1
Golozar, A1
Liu, S1
Lin, JA1
Peairs, K1
Yeh, HC1
Ke, CC1
Hung, CJ1
Chen, DY1
Sheu, WH1
Lui, PW1
Chukwunonso Obi, B1
Chinwuba Okoye, T1
Okpashi, VE1
Nonye Igwe, C1
Olisah Alumanah, E1
Ruiz-Tamayo, I1
Franch-Nadal, J1
Mata-Cases, M1
Mauricio, D1
Cos, X1
Rodriguez-Poncelas, A1
Barrot, J1
Coll-de-Tuero, G1
Mundet-Tudurí, X1
Oh, BY1
Park, YA1
Huh, JW1
Cho, YB1
Yun, SH1
Lee, WY1
Park, HC1
Choi, DH1
Park, YS1
Kim, HC1
Stiefelhagen, P1
Wan, G1
Chen, P1
Pan, D1
Li, L1
Cao, F1
Schwartz, SS1
Jellinger, PS1
Herman, ME1
Jain, D1
Chhoda, A1
Uribe, J1
Kaneuchi, M1
Ou, HT1
Chen, YT1
Liu, YM1
Wu, JS1
Teng, Y1
Lv, X1
Yin, Y1
Kalra, S1
Atreja, A1
Alkhatib, Y1
Abdel Rahman, Z1
Kuriakose, P1
Andrews, TJ1
Cox, RD1
Parker, C1
Kolb, J1
Tabatabaei-Malazy, O1
Nikfar, S1
Larijani, B1
Abdollahi, M1
Du, J1
Feng, W1
Lu, B1
Amizuka, N1
Mayer, MJ1
Klotz, LH1
Venkateswaran, V1
Jiang, H1
Wang, YH1
Wei, CX1
Liu, HC1
Liu, XQ1
Kwon, JS1
Albert, AY1
Gill, S1
Hutcheon, JA1
Sano, H1
Tajima, N1
Correia, S1
Carvalho, C1
Santos, MS1
Seiça, R2
Oliveira, CR1
Moreira, PI1
Haffner, S1
Ratner, RE1
Fowler, SE1
Mather, K1
Marcovina, S1
Saudek, C1
Matulik, MJ1
Price, D1
van der Meer, RW1
Rijzewijk, LJ1
de Jong, HW1
Lamb, HJ1
Lubberink, M1
Romijn, JA1
Bax, JJ1
de Roos, A1
Kamp, O1
Paulus, WJ1
Heine, RJ1
Lammertsma, AA1
Smit, JW1
Diamant, M1
Gropler, RJ1
Fonseca, VA1
St Charles, M1
Minshall, ME2
Pandya, BJ1
Baran, RW1
Tunis, SL1
Nicholson, G1
Dormuth, CR1
Maclure, M1
Carney, G1
Schneeweiss, S1
Bassett, K1
Wright, JM1
Waisundara, VY1
Hsu, A1
Tan, BK1
Huang, D1
Gould, M1
Sellin, JH1
Rowan, JA1
Hague, WM1
McIntyre, HD1
Rigla Cros, M1
Hassan, MM1
Curley, SA1
Kaseb, A1
Davila, M1
Abdalla, EK1
Javle, M1
Moghazy, DM1
Lozano, RD1
Abbruzzese, JL2
Vauthey, JN1
Berlie, HD1
Garwood, CL1
Monte, SV1
Schentag, JJ1
Adelman, MH1
Paladino, JA1
Langmár, Z1
Lavernia, F1
Shubrook, J1
Chowdhury, TA1
Simons, WR1
Hagan, MA1
Macisaac, RJ1
Jerums, G1
Bramlage, P1
Binz, C1
Gitt, AK1
Krekler, M1
Plate, T1
Deeg, E1
Tschöpe, D1
Evans, JM1
Doney, AS1
AlZadjali, MA1
Ogston, SA1
Petrie, JR1
Morris, AD2
Wong, AK1
Ohaeri, JU1
Akanji, AO1
Jermendy, G1
Jansen, HJ1
Vervoort, G1
van der Graaf, M1
Tack, CJ1
Matafome, P1
Louro, T1
Rodrigues, L1
Crisóstomo, J1
Nunes, E1
Amaral, C1
Monteiro, P1
Cipriano, A1
Berstein, LM1
Boyarkina, MP1
Teslenko, SY1
Pratipanawatr, T1
Rawdaree, P1
Chetthakul, T1
Bunnag, P1
Ngarmukos, C1
Benjasuratwong, Y1
Leelawatana, R1
Kosachunhanun, N1
Plengvidhya, N1
Deerochanawong, C1
Suwanwalaikorn, S1
Krittiyawong, S1
Mongkolsomlit, S1
Komoltri, C1
Kourelis, TV1
Siegel, RD1
Alfarouk, KO1
Bashir, AH1
Magruder, JT1
Elahi, D1
Skandalis, K1
Spirova, M1
Gaitanis, G1
Tsartsarakis, A1
Bassukas, ID1
Webster, MW1
Rosta, A1
White, AJ1
Kellar, I1
Prevost, AT1
Kinmonth, AL1
Sutton, S1
Canny, M1
Griffin, SJ1
Wang, P2
Kang, D1
Cao, W1
Reid, TS1
Lee, JH1
Kim, TI1
Jeon, SM1
Hong, SP1
Cheon, JH1
Kim, WH1
Pandey, A1
Forte, V1
Abdallah, M1
Alickaj, A1
Mahmud, S1
Asad, S1
McFarlane, SI1
Sullivan, SD1
Umans, JG1
Ratner, R1
Panossian, Z1
Drury, PL1
Cundy, T1
Mathiesen, ER1
Ringholm, L1
Damm, P1
Gallagher, AM1
Smeeth, L1
Seabroke, S1
Leufkens, HG1
van Staa, TP1
Gallagher, EJ1
LeRoith, D1
Qaseem, A1
Humphrey, LL1
Sweet, DE1
Starkey, M1
Shekelle, P1
Pollak, M1
Sadeghi, N1
Yeung, SC1
Hassan, M1
Shliakhto, EV1
Cappelli, C1
Rotondi, M1
Pirola, I1
Agosti, B1
Formenti, A1
Zarra, E1
Valentini, U1
Leporati, P1
Chiovato, L1
Castellano, M1
Brower, V1
Stevens, RJ1
Ali, R1
Bankhead, CR1
Bethel, MA1
Cairns, BJ1
Camisasca, RP1
Crowe, FL1
Farmer, AJ1
Harrison, S1
Hirst, JA1
Home, P1
McLellan, JH1
Perera, R1
Plüddemann, A1
Ramachandran, A1
Roberts, NW1
Rose, PW1
Schweizer, A1
Viberti, G1
Holman, RR1
Skinner, HD1
McCurdy, MR1
Echeverria, AE1
Lin, SH1
Welsh, JW1
O'Reilly, MS1
Hofstetter, WL1
Ajani, JA1
Komaki, R1
Cox, JD1
Sandulache, VC1
Myers, JN1
Guerrero, TM1
Yang, JD1
Slettedahl, SW1
Fredericksen, ZS1
Gores, GJ1
Olson, JE1
Ampuero, J1
Ranchal, I1
Nuñez, D1
Díaz-Herrero, Mdel M1
Maraver, M1
del Campo, JA1
Camacho, I1
Figueruela, B1
Bautista, JD1
Romero-Gómez, M1
Singh, V1
Gupta, P1
Khatana, S1
Bhagol, A1
Wahlqvist, ML1
Lee, MS1
Chuang, SY1
Tsai, HN1
Yu, SH1
Chang, HY1
Haq, S1
Ali, S1
Mohammad, R1
Sarkar, FH1
Kumar, S1
Meuter, A1
Thapa, P1
Langstraat, C1
Giri, S1
Chien, J1
Rattan, R1
Cliby, W1
Shridhar, V1
Mongraw-Chaffin, ML1
Matsushita, K1
Brancati, FL1
Astor, BC1
Coresh, J1
Crawford, SO1
Schmidt, MI1
Hoogeveen, RC1
Ballantyne, CM1
Young, JH1
Jost, U1
Böhrer, H1
Tankova, T1
Koev, D1
Dakovska, L1
Kirilov, G1
von Keinbaum, P1
Peters, J1
Meir, A1
Kleinman, Y1
Rund, D1
Da'as, N1
Scarpitta, AM1
Sinagra, D1
Orban, JC1
Giunti, C1
Levraut, J1
Grimaud, D1
Ichai, C1
Masoudi, FA1
Inzucchi, SE1
Setaro, JF1
Havranek, EP1
Foody, JM1
Krumholz, HM1
Vigouroux, C1
Satoh, J1
Siraj, ES1
Scarpello, JH1
Schäfers, RF1
Beisswenger, P1
Ruggiero-Lopez, D1
Plank, J1
Bock, GM1
Ajossa, S1
Guerriero, S1
Paoletti, AM1
Orrù, M1
Melis, GB1
Kao, J1
Tobis, J1
McClelland, RL1
Heaton, MR1
Davis, BR1
Holmes, DR1
Currier, JW1
Tan, HH1
McMurdo, ME1
Palmer, AJ2
Roze, S2
Lammert, M1
Nicklasson, L1
Gall, MA1
Spinas, GA1
Seino, H1
Hiraizumi, M1
Harmon, C1
Willoughby, DF1
Floyd, C1
Johnson, JA1
Majumdar, SR1
Fang, ZY1
Schull-Meade, R1
Downey, M1
Prins, J1
Marwick, TH1
Miranda, PJ1
DeFronzo, RA1
Califf, RM1
Guyton, JR1
McCarty, MF1
Yki-Järvinen, H1
Westerbacka, J1
Eddy, DM1
Schlessinger, L1
Kahn, R1
Becker, C1
Luginbühl, A1
Pittl, U1
Schlienger, R1
Gungor, N1
Hannon, T1
Libman, I1
Bacha, F1
Arslanian, S1
Tangelder, GJ1
Dubbelman, M1
Ringens, PJ1
Friesecke, S1
Abel, P1
Kraft, M1
Gerner, A1
Runge, S1
Schnell, O1
Beale, S1
Bagust, A3
Shearer, AT3
Martin, A1
Hulme, L1
Liebl, A1
Schoeffski, O1
Goertz, A1
Ampudia-Blasco, FJ1
Martínez-Lage Alvarez, B1
Pérez Escolano, I1
París, G1
Ong, CR1
Molyneaux, LM1
Constantino, MI1
Twigg, SM1
Yue, DK1
Yurgin, N1
Secnik, K1
Lage, MJ1
Girardin, CM1
Schwitzgebel, VM1
Chodorowski, Z1
Sein Anand, J1
Hellmann, A1
Prejzner, W1
Pipili, C1
Cholongitas, E1
Janka, HU1
Hessel, F1
Walzer, S1
Mã Ller, E1
Pollack, MN1
Chirakup, S1
Chaiyakunapruk, N1
Chaikledkeaw, U1
Pongcharoensuk, P1
Ongphiphadhanakul, B1
Alemao, E1
Yin, D1
Cook, J1
Zeyfang, A1
Trischitta, V1
Gullo, D1
Pezzino, V1
Vigneri, R1
Joffroy-Lavieuville, M1
Triadou, N1
Noel, M2
Beaudot, C1
Merceron, RE1
Lavieuville, M1
Brohon, J1
Raymond, JP1
Davis, TM1
Parsons, RW1
Broadhurst, RJ1
Hobbs, MS1
Jamrozik, K1
Gilbert, RE1
Cooper, ME1
Krum, H1
Flórez, H1
Casanova, P1
Mourlhon, C1
Bergeret, A1
Lacroix, C1
Timsit, J1
Dubois-Laforgue, D1
Yeromenko, Y1
Lavie, L1
Levy, Y1
Glueck, CJ1
Kobayashi, S1
Phillips, H1
Sieve-Smith, L1
Bischoff, A1
Christiansen, AL1
Madsbad, S1
Fedele, D1
Tiengo, A1
Nosadini, R1
Marchiori, E1
Briani, G1
Garotti, MC1
Muggeo, M1
Luft, D1
Schmülling, RM1
Eggstein, M1
Shenfield, GM1
Campbell, CJ1
Duncan, LJ1
Burden, AC1
Thurston, H1
Soler, NG1
Bennett, MA1
Pentecost, BL1
Fitzgerald, MG1
Malins, JM1
Prinseau, J1
Jardin, F1
Sanchez, A1
Baglin, A1
Domart, M1
Lubetzki, J1
Margairaz, A1
Fritel, D1
Debussche, X1
Fournier, A1
Quichaud, J1
Kenworthy, CW1
Schneider, T1
Lopis, S1
Duwoos, H1
Bertrand, CM1
Husson, A1
Cramer, J1
Tayot, J1

Clinical Trials (24)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study[NCT01794143]Phase 35,047 participants (Actual)Interventional2013-05-31Completed
Early Prevention of Diabetes Complications in People With Hyperglycaemia in Europe: e-PREDICE Study[NCT03222765]1,000 participants (Anticipated)Interventional2015-03-15Recruiting
Feasibility of the FreeStyle Libre Continuous Glucose Monitoring System in Youth With Type 2 Diabetes (FREE_CGM)[NCT06089070]30 participants (Anticipated)Interventional2023-12-01Not yet recruiting
Long-term Post-Intervention Follow-up of the TODAY Cohort (Treatment Options for Type 2 Diabetes in Youth and Adolescents)[NCT02310724]517 participants (Actual)Observational2014-03-01Completed
TODAY2 Phase 1 Immediate Post-Intervention Observational Follow-up Study of the TODAY Clinical Trial Cohort[NCT01364350]550 participants (Actual)Observational2011-03-31Completed
Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients[NCT01282060]986 participants (Actual)Observational2009-03-31Active, not recruiting
Efficacy of Metformin for Sputum Conversion in Patients With Active Pulmonary Tuberculosis: A Randomized Controlled Trial[NCT05215990]Phase 1/Phase 280 participants (Anticipated)Interventional2022-01-15Recruiting
A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744]Phase 2112 participants (Anticipated)Interventional2021-08-03Recruiting
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632]Phase 3104 participants (Anticipated)Interventional2016-12-31Not yet recruiting
The Emirates Heart Health Project: A Stepped-wedge Cluster Randomized-controlled Trial of a Family-based Health Coach Guided Dietary and Exercise Intervention for Reducing Weight and Cardiovascular Risk in Overweight and Obese Adult Nationals of the Unite[NCT04688684]80 participants (Anticipated)Interventional2022-06-01Not yet recruiting
"Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Metformin, an Activator of AMPK, on Cognitive Measures of Progression in Huntington's Disease Patients"[NCT04826692]Phase 360 participants (Anticipated)Interventional2021-12-10Recruiting
Endometrial Cancer Recurrence in Patients Taking Metformin[NCT05192850]100 participants (Anticipated)Observational2021-12-27Active, not recruiting
Metformin in Gestational Diabetes and type2 Diabetes in Pregnancy in a Developing Country[NCT01855763]Phase 2/Phase 3300 participants (Actual)Interventional2008-12-31Active, not recruiting
Effect of Adding Metformin to Insulin in Uncontrolled Diabetic Patients During the 3rd Trimester of Pregnancy on Glycemic Control, Fetal and Neonatal Outcomes ,Randomized Controlled Trial[NCT05479214]Phase 4150 participants (Actual)Interventional2022-07-29Completed
Effect of Metformin in Combination With R-CHOP for the First Line Treatment of Patients With Diffuse Large B-cell Lymphoma[NCT03200015]Phase 215 participants (Actual)Interventional2017-10-01Completed
[NCT00004992]Phase 33,234 participants (Actual)Interventional1996-07-31Completed
Magnetic Resonance Assessment of Victoza Efficacy in the Regression of Cardiovascular Dysfunction In Type 2 Diabetes Mellitus[NCT01761318]Phase 450 participants (Actual)Interventional2013-11-30Completed
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547]Phase 220 participants (Anticipated)Interventional2019-01-31Not yet recruiting
The Effect of a Checklist on the Education of Simulated Patients During Insulin Initiation: a Randomized Controlled Trial[NCT02266303]100 participants (Anticipated)Interventional2014-07-31Recruiting
The Effect of a Checklist on the Quality of Education During Insulin Initiation by Trained Medical Students: a Randomized Controlled Trial[NCT02313805]100 participants (Anticipated)Interventional2014-07-31Recruiting
Metformin and Neo-adjuvant Temozolomide and Hypofractionated Accelerated Limited-margin Radiotherapy Followed by Adjuvant Temozolomide in Patients With Glioblastoma Multiforme (M-HARTT STUDY)[NCT02780024]Phase 250 participants (Anticipated)Interventional2015-03-31Active, not recruiting
Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692]Phase 3500 participants (Anticipated)Interventional2021-08-31Suspended (stopped due to Administrative decision of the investigation direction)
Evaluation of Longevity Diet and Fasting Mimicking Diet Programs on Body Composition, Disease Risk Factors, and Aging Markers: a Randomized Clinical Trial[NCT05698654]501 participants (Anticipated)Interventional2023-01-30Recruiting
Effects of Metformin on Fertility and Pregnancy in Women With Polycystic Ovary Syndrome: a Randomized, Prospective, Placebo-controlled Multicenter Study[NCT00994812]Phase 3326 participants (Actual)Interventional2002-08-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

88 reviews available for metformin and Complications of Diabetes Mellitus

ArticleYear
Metformin in cardiovascular diabetology: a focused review of its impact on endothelial function.
    Theranostics, 2021, Volume: 11, Issue:19

    Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Cardiovascular Disease

2021
Exploring the Comparative Efficacy of Metformin and Resveratrol in the Management of Diabetes-associated Complications: A Systematic Review of Preclinical Studies.
    Nutrients, 2020, Mar-11, Volume: 12, Issue:3

    Topics: Animals; Antioxidants; Diabetes Complications; Dietary Supplements; Drug Therapy, Combination; Human

2020
Dissecting the interaction between COVID-19 and diabetes mellitus.
    Journal of diabetes investigation, 2020, Volume: 11, Issue:5

    Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Blood Glucose; Chloroquine; Comorbidity; COVID-

2020
Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
    International journal of molecular sciences, 2020, Aug-23, Volume: 21, Issue:17

    Topics: Diabetes Complications; Drug Resistance, Neoplasm; Endometrial Neoplasms; Estrogens; Female; Glucose

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Insulin resistant diabetes mellitus in SHORT syndrome: case report and literature review.
    Endocrine journal, 2021, Jan-28, Volume: 68, Issue:1

    Topics: Brazil; Canagliflozin; Child; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination;

2021
Current Status and Application of Metformin for Prostate Cancer: A Comprehensive Review.
    International journal of molecular sciences, 2020, Nov-12, Volume: 21, Issue:22

    Topics: AMP-Activated Protein Kinase Kinases; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Pr

2020
The Efficacy and Potential Mechanisms of Metformin in the Treatment of COVID-19 in the Diabetics: A Systematic Review.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: COVID-19; COVID-19 Drug Treatment; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic A

2021
Efficacy of Various Hypoglycemic Agents in the Treatment of Patients With Nonalcoholic Liver Disease With or Without Diabetes： A Network Meta-Analysis.
    Frontiers in endocrinology, 2021, Volume: 12

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Bayes Theorem; Blood Glucose; Body Mass Index; Bo

2021
Diabetes and coronavirus (SARS-CoV-2): Molecular mechanism of Metformin intervention and the scientific basis of drug repurposing.
    PLoS pathogens, 2021, Volume: 17, Issue:6

    Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Diabetes Com

2021
Metformin, Macrophage Dysfunction and Atherosclerosis.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Animals; Atherosclerosis; Biomarkers; Cardiometabolic Risk Factors; Cell Plasticity; Diabetes Compli

2021
Metformin use and the risk of colorectal adenoma: A systematic review and meta-analysis.
    Journal of gastroenterology and hepatology, 2017, Volume: 32, Issue:5

    Topics: Adenoma; Colorectal Neoplasms; Databases, Bibliographic; Diabetes Complications; Diabetes Mellitus;

2017
Meta-analysis of studies using metformin as a reducer for liver cancer risk in diabetic patients.
    Medicine, 2017, Volume: 96, Issue:19

    Topics: Animals; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Liver Neoplasms; Me

2017
Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy.
    Expert opinion on pharmacotherapy, 2017, Volume: 18, Issue:18

    Topics: Bone Density; Canagliflozin; Diabetes Complications; Diabetes Mellitus; Fractures, Bone; Humans; Hyp

2017
A clinical update on metformin and lung cancer in diabetic patients.
    Panminerva medica, 2018, Volume: 60, Issue:2

    Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Apoptosis; Cell Cycle; Clinical Trials as T

2018
Epigenetic effects of metformin: From molecular mechanisms to clinical implications.
    Diabetes, obesity & metabolism, 2018, Volume: 20, Issue:7

    Topics: Acetylation; Animals; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; DN

2018
Body Weight Considerations in the Management of Type 2 Diabetes.
    Advances in therapy, 2019, Volume: 36, Issue:1

    Topics: Blood Glucose; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase

2019
Prevention of Diabetes Mellitus in Patients With Prediabetes.
    The American journal of cardiology, 2019, 02-01, Volume: 123, Issue:3

    Topics: Cost Savings; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Life S

2019
Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
    Journal of medical economics, 2019, Volume: 22, Issue:4

    Topics: Administration, Oral; Age Factors; Age of Onset; Benzhydryl Compounds; Body Weight; China; Cholester

2019
Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis.
    BioMed research international, 2019, Volume: 2019

    Topics: Alcoholism; Diabetes Complications; Diabetes Mellitus; Glucose; Hepacivirus; Hepatitis B; Hepatitis

2019
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?
    Diabetologia, 2019, Volume: 62, Issue:8

    Topics: Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes

2019
For colorectal cancer patients with type II diabetes, could metformin improve the survival rate? A meta-analysis.
    Clinics and research in hepatology and gastroenterology, 2020, Volume: 44, Issue:1

    Topics: Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents

2020
Diabetes and cancer: placing the association in perspective.
    Current opinion in endocrinology, diabetes, and obesity, 2013, Volume: 20, Issue:2

    Topics: Blood Glucose; Carcinoma, Pancreatic Ductal; Cell Transformation, Neoplastic; Diabetes Complications

2013
Type 2 diabetes mellitus in children and youth.
    Indian journal of pediatrics, 2013, Volume: 80 Suppl 1

    Topics: Adolescent; Child; Cross-Sectional Studies; Developing Countries; Diabetes Complications; Diabetes M

2013
Diabetes and bone health.
    Maturitas, 2013, Volume: 76, Issue:3

    Topics: Bone and Bones; Bone Density; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents

2013
[Management of type 2 diabetes: new or previous agents, how to choose?].
    Presse medicale (Paris, France : 1983), 2013, Volume: 42, Issue:5

    Topics: Administration, Oral; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Pep

2013
[Diabetes mellitus related common medical disorders: recent progress in diagnosis and treatment. Topics: I. Pathophysiology, diagnosis and treatment; 6. Diabetes and cancer].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2013, Apr-10, Volume: 102, Issue:4

    Topics: Diabetes Complications; Humans; Insulin; Japan; Metformin; Neoplasms; Risk Factors; Treatment Outcom

2013
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review.
    PloS one, 2013, Volume: 8, Issue:8

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Top

2013
Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world.
    Pharmacoepidemiology and drug safety, 2013, Volume: 22, Issue:10

    Topics: Contraindications; Diabetes Complications; Diabetes Mellitus; Global Health; Guidelines as Topic; Hu

2013
Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease.
    Discovery medicine, 2013, Volume: 16, Issue:90

    Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Animals; Clinical Trials as Topic; Cognition Diso

2013
The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:8

    Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Diabetes Complications; Endometrial N

2014
Diabetes and gastric cancer: the potential links.
    World journal of gastroenterology, 2014, Feb-21, Volume: 20, Issue:7

    Topics: Asian People; Comorbidity; Diabetes Complications; Diabetes Mellitus; Feeding Behavior; Female; Heli

2014
Methylglyoxal in diabetes: link to treatment, glycaemic control and biomarkers of complications.
    Biochemical Society transactions, 2014, Volume: 42, Issue:2

    Topics: Animals; Diabetes Complications; Glycation End Products, Advanced; Humans; Mass Spectrometry; Metfor

2014
Synergism between metformin and statins in modifying the risk of biochemical recurrence following radical prostatectomy in men with diabetes.
    Prostate cancer and prostatic diseases, 2015, Volume: 18, Issue:1

    Topics: Aged; Clinical Trials as Topic; Diabetes Complications; Disease-Free Survival; Drug Synergism; Human

2015
Diabetes mellitus as a novel risk factor for gastrointestinal malignancies.
    Postgraduate medicine, 2014, Volume: 126, Issue:6

    Topics: Adenocarcinoma; Carcinoma, Hepatocellular; Colorectal Neoplasms; Diabetes Complications; Humans; Hyp

2014
Association between metformin therapy and incidence, recurrence and mortality of prostate cancer: evidence from a meta-analysis.
    Diabetes/metabolism research and reviews, 2015, Volume: 31, Issue:6

    Topics: Aged; Anticarcinogenic Agents; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Med

2015
Recent advances in the use of metformin: can treating diabetes prevent breast cancer?
    BioMed research international, 2015, Volume: 2015

    Topics: Breast Neoplasms; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Diabetes C

2015
Hypoglycaemic therapy in type 2 diabetes. Part I. Metformin is the only glucose-lowering drug known to prevent complications of diabetes.
    Prescrire international, 2015, Volume: 24, Issue:159

    Topics: Biomarkers; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Evidence-Based Medicin

2015
Diabetes mellitus and gynecologic cancer: molecular mechanisms, epidemiological, clinical and prognostic perspectives.
    Archives of gynecology and obstetrics, 2016, Volume: 293, Issue:2

    Topics: Diabetes Complications; Diabetes Mellitus; Energy Metabolism; Female; Genital Neoplasms, Female; Hum

2016
Does Metformin Reduce Cancer Risks? Methodologic Considerations.
    Current diabetes reports, 2016, Volume: 16, Issue:1

    Topics: Animals; Bias; Diabetes Complications; Diabetes Mellitus; Humans; Metformin; Neoplasms; Observationa

2016
Metformin therapy associated with survival benefit in lung cancer patients with diabetes.
    Oncotarget, 2016, Jun-07, Volume: 7, Issue:23

    Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Lung Neoplasms; Metformin

2016
Obviating much of the need for insulin therapy in type 2 diabetes mellitus: A re-assessment of insulin therapy's safety profile.
    Postgraduate medicine, 2016, Volume: 128, Issue:6

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes

2016
Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities.
    Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:18

    Topics: Child; Clinical Trials as Topic; Comorbidity; Diabetes Complications; Diabetes Mellitus, Type 2; Hum

2016
[Current evidence-based medicine for early intervention in diabetes].
    Nihon rinsho. Japanese journal of clinical medicine, 2008, Volume: 66, Issue:10

    Topics: Diabetes Complications; Diabetes Mellitus; Diet, Diabetic; Evidence-Based Medicine; Exercise Therapy

2008
Mechanisms of action of metformin in type 2 diabetes and associated complications: an overview.
    Mini reviews in medicinal chemistry, 2008, Volume: 8, Issue:13

    Topics: Animals; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropat

2008
Diabetes medications related to an increased risk of falls and fall-related morbidity in the elderly.
    The Annals of pharmacotherapy, 2010, Volume: 44, Issue:4

    Topics: Accidental Falls; Aged; Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Metformin; Ris

2010
Epidemiological aspects of neoplasms in diabetes.
    Acta diabetologica, 2010, Volume: 47, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Hepatocellular; Case-Control Studies; Cell Divis

2010
Improving glycemic control and cardiometabolic risk through integrated treatment plans.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Glycated Hemoglobin; Glycemi

2010
Risks and benefits of attaining HbA(1c) goals: examining the evidence.
    The Journal of the American Osteopathic Association, 2010, Volume: 110, Issue:7 Suppl 7

    Topics: Algorithms; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Glycated Hemoglobin; G

2010
Diabetes and cancer.
    QJM : monthly journal of the Association of Physicians, 2010, Volume: 103, Issue:12

    Topics: Adipokines; Diabetes Complications; Diabetes Mellitus; Epigenesis, Genetic; Female; Humans; Hyperins

2010
Intensive glucose control and cardiovascular outcomes in type 2 diabetes.
    Heart, lung & circulation, 2011, Volume: 20, Issue:10

    Topics: Age Factors; Blood Glucose; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Typ

2011
Metabolic syndrome in severe mental disorders.
    Metabolic syndrome and related disorders, 2011, Volume: 9, Issue:2

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Environment; Humans; Lif

2011
[New clinical data with metformin therapy in patients with diabetes mellitus].
    Orvosi hetilap, 2010, Dec-05, Volume: 151, Issue:49

    Topics: Administration, Oral; Adult; Aged; Biomarkers; Clinical Trials as Topic; Diabetes Complications; Dia

2010
Metformin and cancer: new applications for an old drug.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms

2012
Diabetes and pancreatic cancer: chicken or egg?
    Pancreas, 2011, Volume: 40, Issue:3

    Topics: Biomarkers, Tumor; Case-Control Studies; Causality; Diabetes Complications; Diabetes Mellitus; Diabe

2011
Clinical practice and implications of recent diabetes trials.
    Current opinion in cardiology, 2011, Volume: 26, Issue:4

    Topics: Blood Glucose; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Complications; Diabetes M

2011
[Diabetes and cancer risk: oncologic considerations].
    Orvosi hetilap, 2011, Jul-17, Volume: 152, Issue:29

    Topics: Adipokines; Age Factors; Animals; Cytokines; Diabetes Complications; Diabetes Mellitus, Type 2; Feed

2011
Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis.
    Diabetes/metabolism research and reviews, 2012, Volume: 28, Issue:2

    Topics: Carcinoma, Hepatocellular; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Me

2012
Diabetes mellitus and the risk of cancer.
    Minerva endocrinologica, 2011, Volume: 36, Issue:3

    Topics: Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Humans; Hypoglycemic A

2011
Gestational diabetes: implications for cardiovascular health.
    Current diabetes reports, 2012, Volume: 12, Issue:1

    Topics: Biomarkers; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetes, Ge

2012
Diabetes, cancer, and metformin: connections of metabolism and cell proliferation.
    Annals of the New York Academy of Sciences, 2011, Volume: 1243

    Topics: Androgens; Animals; Caloric Restriction; Cell Proliferation; Diabetes Complications; Diabetes Mellit

2011
Diabetes and pancreatic cancer.
    Endocrine-related cancer, 2012, Volume: 19, Issue:5

    Topics: Animals; Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen

2012
Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials.
    Diabetologia, 2012, Volume: 55, Issue:10

    Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Humans; Hypoglyce

2012
The complexities of epidemiology and prevention of gastrointestinal cancers.
    International journal of molecular sciences, 2012, Oct-01, Volume: 13, Issue:10

    Topics: Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Diabetes Complications; Folic Acid; Gastrointesti

2012
[Perioperative metformin and lactacidosis].
    Der Anaesthesist, 2002, Volume: 51, Issue:10

    Topics: Acidosis, Lactic; Anesthesia; Animals; Diabetes Complications; Humans; Hypoglycemic Agents; Intraope

2002
[Lipodystrophies: what treatment?].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 2003

    Topics: Antiviral Agents; Diabetes Complications; Diabetes Mellitus; Diet; Exercise; HIV-Associated Lipodyst

2003
[Insulin-sensitizing agents: metformin and thiazolidinedione derivatives].
    Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:7

    Topics: Adipocytes; Adiponectin; Cyclic AMP-Dependent Protein Kinases; Diabetes Complications; Diabetes Mell

2003
Is there a role for metformin or acarbose as a weight-loss agent in the absence of diabetes?
    Cleveland Clinic journal of medicine, 2003, Volume: 70, Issue:8

    Topics: Acarbose; Diabetes Complications; Humans; Hypoglycemic Agents; Metformin; Obesity; Weight Loss

2003
Improving survival with metformin: the evidence base today.
    Diabetes & metabolism, 2003, Volume: 29, Issue:4 Pt 2

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus

2003
Do effects on blood pressure contribute to improved clinical outcomes with metformin?
    Diabetes & metabolism, 2003, Volume: 29, Issue:4 Pt 2

    Topics: Blood Pressure; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type

2003
Metformin inhibition of glycation processes.
    Diabetes & metabolism, 2003, Volume: 29, Issue:4 Pt 2

    Topics: Azepines; Deoxyglucose; Diabetes Complications; Diabetes Mellitus; Glycation End Products, Advanced;

2003
[Drug treatment of type 2 diabetes].
    Wiener medizinische Wochenschrift (1946), 2003, Volume: 153, Issue:21-22

    Topics: Administration, Oral; Cause of Death; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus,

2003
[Progress in diagnosis of and therapy for diabetic lactic acidosis].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2004, Aug-10, Volume: 93, Issue:8

    Topics: Acid-Base Equilibrium; Acidosis, Lactic; Blood Gas Analysis; Consciousness Disorders; Diabetes Compl

2004
A lesson in early morning hyperglycemia.
    The Nurse practitioner, 2004, Volume: 29, Issue:11

    Topics: Blood Glucose Self-Monitoring; Circadian Rhythm; Diabetes Complications; Dose-Response Relationship,

2004
The fatty liver and insulin resistance.
    Current molecular medicine, 2005, Volume: 5, Issue:3

    Topics: Adiponectin; Adipose Tissue; Alanine Transaminase; Animals; Antiretroviral Therapy, Highly Active; C

2005
Cost-effectiveness of rosiglitazone combination therapy for the treatment of type 2 diabetes mellitus in the UK.
    PharmacoEconomics, 2006, Volume: 24 Suppl 1

    Topics: Combined Modality Therapy; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2;

2006
Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany.
    PharmacoEconomics, 2006, Volume: 24 Suppl 1

    Topics: Administration, Oral; Adult; Aged; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus,

2006
Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain.
    PharmacoEconomics, 2006, Volume: 24 Suppl 1

    Topics: Adult; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi

2006
[Diabetes type 2 in pediatrics: diagnosis and management].
    Revue medicale suisse, 2007, Apr-18, Volume: 3, Issue:107

    Topics: Adolescent; Body Weight; Child; Child, Preschool; Diabetes Complications; Diabetes Mellitus, Type 2;

2007
Insulin, insulin-like growth factors, insulin resistance, and neoplasia.
    The American journal of clinical nutrition, 2007, Volume: 86, Issue:3

    Topics: Diabetes Complications; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Life Style; Metfor

2007
[Specific aspects of diabetes management in the elderly].
    MMW Fortschritte der Medizin, 2005, Feb-17, Volume: 147, Issue:7

    Topics: Acarbose; Age Factors; Aged; Aged, 80 and over; Diabetes Complications; Diabetes Mellitus; Diabetes

2005
[Metformin, lipids and atherosclerosis].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1984

    Topics: Adipose Tissue; Adrenal Glands; Animals; Aorta; Apolipoproteins A; Apolipoproteins B; Arterioscleros

1984
Drug administration in patients with diabetes mellitus. Safety considerations.
    Drug safety, 1998, Volume: 18, Issue:6

    Topics: Acarbose; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Ag

1998
[Should the occurrence of a first coronary event change the management of diabetes?].
    Archives des maladies du coeur et des vaisseaux, 2000, Volume: 93 Spec No 4

    Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Antagonists; Blood Glucose; Cardiovascular Agents;

2000
Homocysteine and cardiovascular risk in patients with diabetes mellitus.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2001, Volume: 11, Issue:2

    Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus; Homocysteine; Humans; Hyperhomocysteine

2001
[The effect of metformin on late diabetic complications and cardiovascular events in obese patients with type 2 diabetes].
    Ugeskrift for laeger, 2002, Apr-08, Volume: 164, Issue:15

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; H

2002
Lactic acidosis in biguanide-treated diabetics: a review of 330 cases.
    Diabetologia, 1978, Volume: 14, Issue:2

    Topics: Acidosis; Biguanides; Buformin; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen

1978
[Management and treatment of lactic acidosis].
    Journees annuelles de diabetologie de l'Hotel-Dieu, 1990

    Topics: Acidosis, Lactic; Bicarbonates; Diabetes Complications; Diabetes Mellitus; Humans; Metformin; Renal

1990

Trials

17 trials available for metformin and Complications of Diabetes Mellitus

ArticleYear
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    The New England journal of medicine, 2022, 09-22, Volume: 387, Issue:12

    Topics: Albuminuria; Blood Glucose; Cardiovascular Diseases; Comparative Effectiveness Research; Diabetes Co

2022
Early prevention of diabetes microvascular complications in people with hyperglycaemia in Europe. ePREDICE randomized trial. Study protocol, recruitment and selected baseline data.
    PloS one, 2020, Volume: 15, Issue:4

    Topics: Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Diabetic Neuropathi

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Clinical therapeutics, 2017, Volume: 39, Issue:7

    Topics: Body Mass Index; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Female; G

2017
Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial.
    Cardiovascular diabetology, 2017, 08-14, Volume: 16, Issue:1

    Topics: Adult; Ascorbic Acid; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, T

2017
Efficacy and tolerability of novel triple combination therapy in drug-naïve patients with type 2 diabetes from the TRIPLE-AXEL trial: protocol for an open-label randomised controlled trial.
    BMJ open, 2018, 09-24, Volume: 8, Issue:9

    Topics: Adamantane; Adult; Benzhydryl Compounds; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptid

2018
Glycemic Control and Insulin Treatment Alter Fracture Risk in Older Men With Type 2 Diabetes Mellitus.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:11

    Topics: Aged; Aged, 80 and over; Bone Density; Diabetes Complications; Diabetes Mellitus, Type 2; Fractures,

2019
Metformin for the treatment of hyperandrogenism in adolescents with type 1 diabetes mellitus.
    Hormone research in paediatrics, 2013, Volume: 80, Issue:5

    Topics: 17-alpha-Hydroxyprogesterone; Adolescent; Adult; Androsterone; Diabetes Complications; Diabetes Mell

2013
The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.
    Diabetic medicine : a journal of the British Diabetic Association, 2015, Volume: 32, Issue:7

    Topics: Benzhydryl Compounds; Cohort Studies; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellit

2015
Saxagliptin is similar in glycaemic variability more effective in metabolic control than acarbose in aged type 2 diabetes inadequately controlled with metformin.
    Diabetes research and clinical practice, 2015, Volume: 108, Issue:3

    Topics: Acarbose; Adamantane; Aged; Aged, 80 and over; Blood Glucose; Diabetes Complications; Diabetes Melli

2015
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
    Journal of diabetes research, 2015, Volume: 2015

    Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu

2015
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
    Journal of diabetes research, 2015, Volume: 2015

    Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu

2015
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
    Journal of diabetes research, 2015, Volume: 2015

    Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu

2015
Metformin treatment in type 2 diabetes in pregnancy: an active controlled, parallel-group, randomized, open label study in patients with type 2 diabetes in pregnancy.
    Journal of diabetes research, 2015, Volume: 2015

    Topics: Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Gestational Age; Hu

2015
Vitamin D status is associated with skin autofluorescence in patients with type 2 diabetes mellitus: a preliminary report.
    Cardiovascular diabetology, 2015, Jul-16, Volume: 14

    Topics: Aged; Cross-Sectional Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Comb

2015
Effect of progression from impaired glucose tolerance to diabetes on cardiovascular risk factors and its amelioration by lifestyle and metformin intervention: the Diabetes Prevention Program randomized trial by the Diabetes Prevention Program Research Gro
    Diabetes care, 2009, Volume: 32, Issue:4

    Topics: Adult; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; D

2009
Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Adenosine Triphosphate; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combi

2009
Glycemia and its relationship to outcomes in the metformin in gestational diabetes trial.
    Diabetes care, 2010, Volume: 33, Issue:1

    Topics: Birth Weight; Diabetes Complications; Diabetes, Gestational; Female; Gestational Age; Glucose Tolera

2010
Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM).
    International journal of clinical pharmacology and therapeutics, 2007, Volume: 45, Issue:12

    Topics: Adult; Aged; Computer Simulation; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, C

2007
HB419 (glibenclamide) in the treatment of diabetes mellitus.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1969, Aug-09, Volume: 43, Issue:32

    Topics: Adult; Age Factors; Aged; Biguanides; Chlorpropamide; Clinical Trials as Topic; Diabetes Complicatio

1969

Other Studies

169 other studies available for metformin and Complications of Diabetes Mellitus

ArticleYear
Impact of overlapping risks of type 2 diabetes and obesity on coronavirus disease severity in the United States.
    Scientific reports, 2021, 09-09, Volume: 11, Issue:1

    Topics: Aged; Aging; COVID-19; COVID-19 Drug Treatment; Critical Care; Diabetes Complications; Diabetes Mell

2021
Metformin use is associated with a lower risk of rotator cuff disease in patients with Type 2 diabetes mellitus.
    Diabetes & metabolism, 2022, Volume: 48, Issue:5

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Female; Glucose; Humans; Hypoglycemic Agents; Inc

2022
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy.
    BMJ open, 2023, 09-29, Volume: 13, Issue:9

    Topics: Cost-Benefit Analysis; Cost-Effectiveness Analysis; Diabetes Complications; Diabetes Mellitus, Type

2023
Metformin Use Is Associated With a Lower Risk of Hospitalization for Heart Failure in Patients With Type 2 Diabetes Mellitus: a Retrospective Cohort Analysis.
    Journal of the American Heart Association, 2019, 11-05, Volume: 8, Issue:21

    Topics: Aged; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Hosp

2019
Association between clinical outcomes and metformin use in adults with sickle cell disease and diabetes mellitus.
    Blood advances, 2019, 11-12, Volume: 3, Issue:21

    Topics: Adult; Anemia, Sickle Cell; Comorbidity; Diabetes Complications; Diabetes Mellitus; Female; Humans;

2019
Oncological benefit of metformin in patients with pancreatic ductal adenocarcinoma and comorbid diabetes mellitus.
    Langenbeck's archives of surgery, 2020, Volume: 405, Issue:3

    Topics: Adult; Aged; Carcinoma, Pancreatic Ductal; Diabetes Complications; Female; Humans; Hypoglycemic Agen

2020
Metformin use reduced the risk of stomach cancer in diabetic patients in Korea: an analysis of Korean NHIS-HEALS database.
    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2020, Volume: 23, Issue:6

    Topics: Adult; Databases, Factual; Diabetes Complications; Diabetes Mellitus; Early Detection of Cancer; Fem

2020
Metformin ameliorates the NLPP3 inflammasome mediated pyroptosis by inhibiting the expression of NEK7 in diabetic periodontitis.
    Archives of oral biology, 2020, Volume: 116

    Topics: Animals; Diabetes Complications; Diabetes Mellitus; Inflammasomes; Metformin; Mice; NIMA-Related Kin

2020
Zinc supplementation improves markers of glucose homeostasis in thalassaemia.
    British journal of haematology, 2020, Volume: 190, Issue:3

    Topics: Adolescent; Adult; Biomarkers; Blood Glucose; C-Peptide; Child; Diabetes Complications; Diabetes Mel

2020
The suggested chemopreventive association of metformin with prostate cancer in diabetic patients.
    Urologic oncology, 2021, Volume: 39, Issue:3

    Topics: Aged; Aged, 80 and over; Chemoprevention; Cohort Studies; Diabetes Complications; Humans; Hypoglycem

2021
Metformin attenuated histopathological ocular deteriorations in a streptozotocin-induced hyperglycemic rat model.
    Naunyn-Schmiedeberg's archives of pharmacology, 2021, Volume: 394, Issue:3

    Topics: Animals; Claudin-1; Diabetes Complications; Diabetes Mellitus, Experimental; Eye Diseases; Glutathio

2021
[Diabetes and COVID-19: analysis of the clinical outcomes according to the data of the russian diabetes registry].
    Problemy endokrinologii, 2020, 08-04, Volume: 66, Issue:1

    Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors;

2020
Prognostic roles of diabetes mellitus and hypertension in advanced hepatocellular carcinoma treated with sorafenib.
    PloS one, 2020, Volume: 15, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Cohort Studies; Di

2020
The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress.
    International immunopharmacology, 2021, Volume: 96

    Topics: Acetates; Animals; Cyclopropanes; Cytochrome P-450 CYP1A2 Inducers; Diabetes Complications; Diabetes

2021
The Relationship of Diabetes Mellitus to Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer.
    Oncology, 2021, Volume: 99, Issue:9

    Topics: Carcinoma, Non-Small-Cell Lung; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agen

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Long-Term Complications in Youth-Onset Type 2 Diabetes.
    The New England journal of medicine, 2021, 07-29, Volume: 385, Issue:5

    Topics: Adolescent; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-

2021
Benefits of Metformin Combined with Pemetrexed-Based Platinum Doublets as a First-Line Therapy for Advanced Lung Adenocarcinoma Patients with Diabetes.
    Biomolecules, 2021, 08-21, Volume: 11, Issue:8

    Topics: Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Diabetes Complications

2021
Reducing CV risk in diabetes: An ADA update.
    The Journal of family practice, 2017, Volume: 66, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications;

2017
Missed Opportunities for Deprescription: A Teachable Moment.
    JAMA internal medicine, 2017, 07-01, Volume: 177, Issue:7

    Topics: Aged, 80 and over; Deprescriptions; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combina

2017
Diabetes-related weight change in a Canadian First Nation cohort.
    International journal of circumpolar health, 2017, Volume: 76, Issue:1

    Topics: Anthropometry; Body Weight; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Femal

2017
Gliptin therapy reduces hepatic and myocardial fat in type 2 diabetic patients.
    European journal of clinical investigation, 2017, Volume: 47, Issue:11

    Topics: Adamantane; Adipose Tissue; Adult; Aged; Cardiomyopathies; Diabetes Complications; Diabetes Mellitus

2017
Metformin accelerates wound healing in type 2 diabetic db/db mice.
    Molecular medicine reports, 2017, Volume: 16, Issue:6

    Topics: Animals; Biomarkers; Blood Glucose; Diabetes Complications; Diabetes Mellitus, Experimental; Diabete

2017
Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes.
    Diabetes care, 2018, Volume: 41, Issue:1

    Topics: Aged; Aged, 80 and over; Blood Pressure; Cardiovascular Diseases; Diabetes Complications; Diabetes M

2018
Protective effect of metformin against retinal vein occlusions in diabetes mellitus - A nationwide population-based study.
    PloS one, 2017, Volume: 12, Issue:11

    Topics: Aged; Diabetes Complications; Female; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Ret

2017
Reactions between methylglyoxal and its scavengers in-vivo appear to be catalyzed enzymatically.
    Medical hypotheses, 2017, Volume: 109

    Topics: Aldehydes; Carbon; Cardiovascular Agents; Catalysis; Diabetes Complications; Dihydroxyacetone; Fruct

2017
In This Issue of
    Diabetes, 2018, Volume: 67, Issue:1

    Topics: Animals; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Diabetic Retinopathy; Hum

2018
[Vitamin B12 Deficiency in Type 2 Diabetes Mellitus].
    Acta medica portuguesa, 2017, Oct-31, Volume: 30, Issue:10

    Topics: Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Male;

2017
14-3-3zeta is involved in the anticancer effect of metformin in colorectal carcinoma.
    Carcinogenesis, 2018, 03-08, Volume: 39, Issue:3

    Topics: 14-3-3 Proteins; Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Color

2018
The effect of metformin on culture conversion in tuberculosis patients with diabetes mellitus.
    The Korean journal of internal medicine, 2018, Volume: 33, Issue:5

    Topics: Adult; Aged; Antitubercular Agents; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypog

2018
Elevated levels of matrix metalloproteinases reflect severity and extent of disease in tuberculosis-diabetes co-morbidity and are predominantly reversed following standard anti-tuberculosis or metformin treatment.
    BMC infectious diseases, 2018, 07-25, Volume: 18, Issue:1

    Topics: Antitubercular Agents; Comorbidity; Diabetes Complications; Diabetes Mellitus; Humans; Matrix Metall

2018
The association of metformin use with prostate cancer aggressiveness among Black Americans and White Americans in a population-based study.
    Cancer causes & control : CCC, 2018, Volume: 29, Issue:11

    Topics: Adult; Aged; Black or African American; Body Mass Index; Diabetes Complications; Diabetes Mellitus;

2018
Cost-effectiveness of intensification with sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes on metformin and sitagliptin vs direct intensification with insulin in the United Kingdom.
    Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:4

    Topics: Adult; Aged; Blood Glucose; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2

2019
RasGRP1 is a target for VEGF to induce angiogenesis and involved in the endothelial-protective effects of metformin under high glucose in HUVECs.
    IUBMB life, 2019, Volume: 71, Issue:9

    Topics: Cell Movement; Diabetes Complications; DNA-Binding Proteins; Endothelial Cells; Gene Expression Regu

2019
Metformin inhibits goitrogenous effects of type 2 diabetes.
    European journal of endocrinology, 2013, Volume: 169, Issue:1

    Topics: Adult; Aged; Biomarkers; Cross-Sectional Studies; Diabetes Complications; Diabetes Mellitus, Type 2;

2013
Inhibitory effect of metformin on bone metastasis of cancer via OPG/RANKL/RANK system.
    Medical hypotheses, 2013, Volume: 81, Issue:5

    Topics: Bone Neoplasms; Diabetes Complications; Gene Expression Regulation, Neoplastic; Humans; Metformin; M

2013
Editorial: diabetes and cancer - disease, drugs or deception?
    Current drug safety, 2013, Volume: 8, Issue:5

    Topics: Breast Neoplasms; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; In

2013
Endothelial cellular senescence is inhibited by liver X receptor activation with an additional mechanism for its atheroprotection in diabetes.
    Proceedings of the National Academy of Sciences of the United States of America, 2014, Jan-21, Volume: 111, Issue:3

    Topics: Administration, Oral; Animals; Aorta; Atherosclerosis; Cellular Senescence; Densitometry; Diabetes C

2014
Therapeutic potential of the anti-diabetic agent metformin in targeting the skin cancer stem cell diaspora.
    Experimental dermatology, 2014, Volume: 23, Issue:5

    Topics: Chemoprevention; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Mel

2014
Enhancement of diabetic wound repair using biodegradable nanofibrous metformin-eluting membranes: in vitro and in vivo.
    ACS applied materials & interfaces, 2014, Mar-26, Volume: 6, Issue:6

    Topics: Animals; Delayed-Action Preparations; Diabetes Complications; Drug Carriers; Female; Humans; Male; M

2014
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
    Diabetes care, 2014, Volume: 37, Issue:5

    Topics: Amputation, Surgical; Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Melli

2014
Diabetes and pancreatic cancer.
    JOP : Journal of the pancreas, 2014, Mar-10, Volume: 15, Issue:2

    Topics: Diabetes Complications; Early Diagnosis; Humans; Metformin; Pancreatic Neoplasms; Risk Factors; Surv

2014
Cost-effectiveness of metformin plus vildagliptin compared with metformin plus sulphonylurea for the treatment of patients with type 2 diabetes mellitus: a Portuguese healthcare system perspective.
    Journal of medical economics, 2014, Volume: 17, Issue:7

    Topics: Adamantane; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, T

2014
Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice.
    The Journal of endocrinology, 2014, Volume: 221, Issue:2

    Topics: Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Combined Modality Therapy; Diabetes Complicat

2014
Continuation of metformin use after a diagnosis of cirrhosis significantly improves survival of patients with diabetes.
    Hepatology (Baltimore, Md.), 2014, Volume: 60, Issue:6

    Topics: Aged; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Liver Cirrhosi

2014
Association between intensification of metformin treatment with insulin vs sulfonylureas and cardiovascular events and all-cause mortality among patients with diabetes.
    JAMA, 2014, Jun-11, Volume: 311, Issue:22

    Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus; Female; Glycated Hemoglobin; Humans; Hypogly

2014
[Vitamin B12 deficiency associated with high doses od metformin in older people diabetic].
    Nutricion hospitalaria, 2014, Jun-01, Volume: 29, Issue:6

    Topics: Aged; Aged, 80 and over; Case-Control Studies; Diabetes Complications; Diabetes Mellitus; Female; Hu

2014
Perioperative management of diabetic patients: new controversies.
    British journal of anaesthesia, 2014, Volume: 113, Issue:6

    Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Administration Schedule; Glyc

2014
Sulfonylurea use and incident cardiovascular disease among patients with type 2 diabetes: prospective cohort study among women.
    Diabetes care, 2014, Volume: 37, Issue:11

    Topics: Aged; Cardiovascular Diseases; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Fe

2014
The evaluation of clinical and cost outcomes associated with earlier initiation of insulin in patients with type 2 diabetes mellitus.
    Journal of managed care & specialty pharmacy, 2014, Volume: 20, Issue:9

    Topics: Cohort Studies; Cost Savings; Costs and Cost Analysis; Diabetes Complications; Diabetes Mellitus, Ty

2014
Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
    European journal of cancer (Oxford, England : 1990), 2014, Volume: 50, Issue:16

    Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Inciden

2014
Diabetic oncopathy--one more yet another deadly diabetic complication!
    The Indian journal of medical research, 2014, Volume: 140, Issue:1

    Topics: Diabetes Complications; Glucose; Humans; Hyperinsulinism; Hypoglycemic Agents; India; Metformin; Mod

2014
Glucose and metformin modulate human first trimester trophoblast function: a model and potential therapy for diabetes-associated uteroplacental insufficiency.
    American journal of reproductive immunology (New York, N.Y. : 1989), 2015, Volume: 73, Issue:4

    Topics: Angiogenesis Inducing Agents; Antigens, CD; Carrier Proteins; Cell Line; Cell Movement; Chemokine CC

2015
Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy.
    Annals of surgery, 2016, Volume: 263, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Diabetes Complications; Female; Gastrectomy; Humans;

2016
Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study.
    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2015, Volume: 34, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Clostridioides difficile; Clostridium Infectio

2015
The Impact of Diabetes Mellitus and Metformin Treatment on Survival of Patients with Advanced Pancreatic Cancer Undergoing Chemotherapy.
    Cancer research and treatment, 2016, Volume: 48, Issue:1

    Topics: Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metformin; Pancreatic Neopla

2016
Association between worse metabolic control and increased thyroid volume and nodular disease in elderly adults with metabolic syndrome.
    Metabolic syndrome and related disorders, 2015, Volume: 13, Issue:5

    Topics: Aged; Aged, 80 and over; Anthropometry; Argentina; Body Mass Index; Cohort Studies; Cross-Sectional

2015
Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
    Diabetes/metabolism research and reviews, 2015, Volume: 31, Issue:6

    Topics: Adult; Aged; Anticarcinogenic Agents; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Typ

2015
Metformin does not improve survival of cholangiocarcinoma patients with diabetes.
    Hepatology (Baltimore, Md.), 2016, Volume: 63, Issue:2

    Topics: Aged; Bile Duct Neoplasms; Cholangiocarcinoma; Diabetes Complications; Diabetes Mellitus; Female; Hu

2016
Metformin may improve the prognosis of patients with pancreatic cancer.
    Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:9

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Meta-Analysis as Top

2015
The Effect of Metformin Use on Left Ventricular Ejection Fraction and Mortality Post-Myocardial Infarction.
    Cardiovascular drugs and therapy, 2015, Volume: 29, Issue:3

    Topics: Case-Control Studies; Cause of Death; Diabetes Complications; Female; Humans; Hypoglycemic Agents; M

2015
Are metformin, statin and aspirin use still associated with overall mortality among colorectal cancer patients with diabetes if adjusted for one another?
    British journal of cancer, 2015, Jul-28, Volume: 113, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; F

2015
[Effective prevention of coronary heart disease by early diabetes therapy].
    MMW Fortschritte der Medizin, 2015, Jul-23, Volume: 157, Issue:13

    Topics: Coronary Disease; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early M

2015
Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction.
    Cardiovascular drugs and therapy, 2015, Volume: 29, Issue:5

    Topics: Diabetes Complications; Female; Humans; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction;

2015
Response to Letter to the Editor: Effects of New Antiplatelet Agents and Aldosterone Receptor Antagonists on Mortality in Patients with Myocardial Infarction.
    Cardiovascular drugs and therapy, 2015, Volume: 29, Issue:5

    Topics: Diabetes Complications; Female; Humans; Hypoglycemic Agents; Male; Metformin; Myocardial Infarction;

2015
Metformin influences progression in diabetic glioblastoma patients.
    Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], 2015, Volume: 191, Issue:12

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Blood Glucose; Brain;

2015
Increased Risk of Herpes Zoster in Diabetic Patients Comorbid with Coronary Artery Disease and Microvascular Disorders: A Population-Based Study in Taiwan.
    PloS one, 2016, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Case-Control Studies; Comorbidity; Coronary Artery Disease; Databases, Fact

2016
Comparative Study of the Antioxidant Effects of Metformin, Glibenclamide, and Repaglinide in Alloxan-Induced Diabetic Rats.
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Alloxan; Animals; Antioxidants; Biomarkers; Blood Glucose; Carbamates; Catalase; Diabetes Complicati

2016
Noninsulin Antidiabetic Drugs for Patients with Type 2 Diabetes Mellitus: Are We Respecting Their Contraindications?
    Journal of diabetes research, 2016, Volume: 2016

    Topics: Adult; Aged; Aged, 80 and over; Comorbidity; Cross-Sectional Studies; Diabetes Complications; Diabet

2016
Metformin enhances the response to radiotherapy in diabetic patients with rectal cancer.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:6

    Topics: Aged; Case-Control Studies; Chemoradiotherapy; Diabetes Complications; Female; Humans; Hypoglycemic

2016
[Metformin - an anti-carcinogenesis drug?].
    MMW Fortschritte der Medizin, 2016, Mar-31, Volume: 158, Issue:6

    Topics: Carcinogenesis; Diabetes Complications; Humans; Metformin; Neoplasms; Octamer Transcription Factor-1

2016
[The risk is higher, but why?].
    MMW Fortschritte der Medizin, 2016, Mar-31, Volume: 158, Issue:6

    Topics: Carcinoma, Hepatocellular; Diabetes Complications; Humans; Liver Neoplasms; Metformin; Neoplasms; Pa

2016
Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and Advanced Adenoma Among DM II.
    Journal of gastrointestinal cancer, 2016, Volume: 47, Issue:4

    Topics: Adenoma; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diabetes Complication

2016
[Diabetes mellitus and endometrial cancer].
    Nihon rinsho. Japanese journal of clinical medicine, 2016, Volume: 74 Suppl 2

    Topics: Animals; Diabetes Complications; Diabetes Mellitus; Endometrial Neoplasms; Female; Humans; Hypoglyce

2016
Comparative cost-effectiveness of metformin-based dual therapies associated with risk of cardiovascular diseases among Chinese patients with type 2 diabetes: Evidence from a population-based national cohort in Taiwan.
    Diabetes research and clinical practice, 2016, Volume: 116

    Topics: Acarbose; Aged; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mel

2016
Metformin Alleviated Aβ-Induced Apoptosis via the Suppression of JNK MAPK Signaling Pathway in Cultured Hippocampal Neurons.
    BioMed research international, 2016, Volume: 2016

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Diabetes Complications; Diabetes Melli

2016
Diabetic tuberculosis.
    JPMA. The Journal of the Pakistan Medical Association, 2016, Volume: 66, Issue:9

    Topics: Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; I

2016
Clinical impact of metformin in diabetic diffuse large B-cell lymphoma patients: a case-control study.
    Leukemia & lymphoma, 2017, Volume: 58, Issue:5

    Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Case-Control Stu

2017
Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor.
    The Journal of emergency medicine, 2017, Volume: 52, Issue:2

    Topics: Acetone; Antihypertensive Agents; Blood Glucose; Canagliflozin; Diabetes Complications; Diabetic Ket

2017
Histological evidence that metformin reverses the adverse effects of diabetes on orthodontic tooth movement in rats.
    Journal of molecular histology, 2017, Volume: 48, Issue:2

    Topics: Alkaline Phosphatase; Animals; Cathepsin K; Diabetes Complications; Diabetes Mellitus, Experimental;

2017
The Effect of Metformin Use during Docetaxel Chemotherapy on Prostate Cancer Specific and Overall Survival of Diabetic Patients with Castration Resistant Prostate Cancer.
    The Journal of urology, 2017, Volume: 197, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Diabetes Complications; Diabetes Mel

2017
A mini-network balance model for evaluating the progression of cardiovascular complications in Goto-Kakizaki rats.
    Acta pharmacologica Sinica, 2017, Volume: 38, Issue:3

    Topics: Alkenes; Animals; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Diseas

2017
Diabetic Pharmacotherapy and Endometrial Cancer Risk Within a Publicly Funded Health Care System.
    Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2017, Volume: 39, Issue:1

    Topics: Aged; Case-Control Studies; Diabetes Complications; Diabetes Mellitus; Endometrial Neoplasms; Female

2017
Lost in translation: modulation of the metabolic-functional relation in the diabetic human heart.
    Circulation, 2009, Apr-21, Volume: 119, Issue:15

    Topics: Animals; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Fatty A

2009
Identification and treatment of prediabetes to prevent progression to type 2 diabetes.
    Clinical cornerstone, 2008, Volume: 9, Issue:2

    Topics: Acarbose; Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus,

2008
A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.
    Current medical research and opinion, 2009, Volume: 25, Issue:6

    Topics: Aged; Comorbidity; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Co

2009
Current therapeutic drugs for type 2 diabetes, still useful after 50 years?
    Anesthesia and analgesia, 2009, Volume: 108, Issue:6

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; History, 20th Century; Humans; Hypoglycemic Agent

2009
Rosiglitazone and myocardial infarction in patients previously prescribed metformin.
    PloS one, 2009, Jun-27, Volume: 4, Issue:6

    Topics: Aged; Case-Control Studies; Cohort Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Femal

2009
Baicalin reduces mitochondrial damage in streptozotocin-induced diabetic Wistar rats.
    Diabetes/metabolism research and reviews, 2009, Volume: 25, Issue:7

    Topics: Animals; Citrate (si)-Synthase; Diabetes Complications; Diabetes Mellitus, Experimental; Flavonoids;

2009
Type 2 diabetes: target HbA1c of about 7%.
    Prescrire international, 2009, Volume: 18, Issue:102

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Follow-Up Studies; Glycate

2009
Diabetic diarrhea.
    Current gastroenterology reports, 2009, Volume: 11, Issue:5

    Topics: Algorithms; Antidiarrheals; Celiac Disease; Clonidine; Colitis; Diabetes Complications; Diabetes Mel

2009
[Glargine insulin and cancer risk].
    Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2009, Volume: 56, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Diabetes Complications; Diabe

2009
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma.
    Cancer, 2010, Apr-15, Volume: 116, Issue:8

    Topics: Adult; Aged; Carcinoma, Hepatocellular; Case-Control Studies; Diabetes Complications; Diabetes Melli

2010
Glucose supply and insulin demand dynamics of antidiabetic agents.
    Journal of diabetes science and technology, 2010, Mar-01, Volume: 4, Issue:2

    Topics: 1-Deoxynojirimycin; Acarbose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Ty

2010
[Diagnosis and treatment of polycystic ovary syndrome].
    Orvosi hetilap, 2010, Apr-04, Volume: 151, Issue:14

    Topics: Acne Vulgaris; Alopecia; Amenorrhea; Androgens; Clomiphene; Diabetes Complications; Diagnosis, Diffe

2010
An economic evaluation of colesevelam when added to metformin-, insulin- or sulfonylurea-based therapies in patients with uncontrolled type 2 diabetes mellitus.
    PharmacoEconomics, 2010, Volume: 28, Issue:9

    Topics: Adult; Aged; Allylamine; Cardiovascular Diseases; Cholesterol, LDL; Colesevelam Hydrochloride; Cost-

2010
Diabetes treatment patterns and goal achievement in primary diabetes care (DiaRegis) - study protocol and patient characteristics at baseline.
    Cardiovascular diabetology, 2010, Sep-16, Volume: 9

    Topics: Adult; Comorbidity; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Ge

2010
Effect of Metformin on mortality in patients with heart failure and type 2 diabetes mellitus.
    The American journal of cardiology, 2010, Oct-01, Volume: 106, Issue:7

    Topics: Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hypoglycemic

2010
Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile.
    The Netherlands journal of medicine, 2010, Volume: 68, Issue:11

    Topics: Aged; Body Fat Distribution; Body Weight; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes

2010
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
    Diabetes/metabolism research and reviews, 2011, Volume: 27, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complicat

2011
Familial diabetes is associated with reduced risk of cancer in diabetic patients: a possible role for metformin.
    Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:2

    Topics: Aged; Case-Control Studies; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Follow-Up Stu

2012
Thailand Diabetic Registry cohort: predicting death in Thai diabetic patients and causes of death.
    Journal of the Medical Association of Thailand = Chotmaihet thangphaet, 2010, Volume: 93 Suppl 3

    Topics: Aged; Asian People; Cardiovascular Diseases; Cause of Death; Diabetes Complications; Diabetes Mellit

2010
Diabetes mellitus type 2 through oncology lens.
    Medical hypotheses, 2011, Volume: 76, Issue:5

    Topics: Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Insulin; Isc

2011
Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin.
    Journal of the European Academy of Dermatology and Venereology : JEADV, 2012, Volume: 26, Issue:2

    Topics: Diabetes Complications; Diabetes Mellitus; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic

2012
Adherence to hypoglycaemic medication among people with type 2 diabetes in primary care.
    Primary care diabetes, 2012, Volume: 6, Issue:1

    Topics: Administration, Oral; Aged; Ambulatory Care Facilities; Diabetes Complications; Diabetes Mellitus, T

2012
Options for intensifying diabetes treatment.
    The Journal of family practice, 2011, Volume: 60, Issue:9 Suppl

    Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Health Status

2011
The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus.
    International journal of cancer, 2012, Aug-01, Volume: 131, Issue:3

    Topics: Adult; Aged; Aged, 80 and over; Colorectal Neoplasms; Diabetes Complications; Diabetes Mellitus; Fem

2012
Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment.
    Diabetologia, 2012, Volume: 55, Issue:1

    Topics: Aged; Aged, 80 and over; Contraindications; Diabetes Complications; Diabetes Mellitus, Type 2; Drug

2012
Pregnancy management of women with pregestational diabetes.
    Endocrinology and metabolism clinics of North America, 2011, Volume: 40, Issue:4

    Topics: Congenital Abnormalities; Counseling; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Me

2011
Risk of death and cardiovascular outcomes with thiazolidinediones: a study with the general practice research database and secondary care data.
    PloS one, 2011, Volume: 6, Issue:12

    Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Cardiovascular Diseases; Cohort Studies; Databases

2011
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
    Annals of internal medicine, 2012, Feb-07, Volume: 156, Issue:3

    Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp

2012
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
    Annals of internal medicine, 2012, Feb-07, Volume: 156, Issue:3

    Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp

2012
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
    Annals of internal medicine, 2012, Feb-07, Volume: 156, Issue:3

    Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp

2012
Oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
    Annals of internal medicine, 2012, Feb-07, Volume: 156, Issue:3

    Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp

2012
Summaries for patients: Oral drug treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians.
    Annals of internal medicine, 2012, Feb-07, Volume: 156, Issue:3

    Topics: Administration, Oral; Age Factors; Cause of Death; Comparative Effectiveness Research; Diabetes Comp

2012
Metformin and pancreatic cancer: a clue requiring investigation.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-15, Volume: 18, Issue:10

    Topics: Antineoplastic Agents; Diabetes Complications; Diabetes Mellitus; Humans; Hypoglycemic Agents; Metfo

2012
Metformin use is associated with better survival of diabetic patients with pancreatic cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, May-15, Volume: 18, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglyce

2012
[Molecular and genetic aspects of heart failure in diabetic patients].
    Vestnik Rossiiskoi akademii meditsinskikh nauk, 2012, Issue:1

    Topics: Biotransformation; Cardiotonic Agents; Cardiovascular Agents; Diabetes Complications; Drug Delivery

2012
Thyreotropin levels in diabetic patients on metformin treatment.
    European journal of endocrinology, 2012, Volume: 167, Issue:2

    Topics: Adult; Aged; Autoantibodies; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypoglycemic

2012
Illuminating the diabetes-cancer link.
    Journal of the National Cancer Institute, 2012, Jul-18, Volume: 104, Issue:14

    Topics: Animals; Antineoplastic Agents; Apoptosis; Blood Glucose; Breast Neoplasms; Clinical Trials as Topic

2012
Metformin use and improved response to therapy in esophageal adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Diabetes Complications; Diabetes

2013
Early, aggressive treatment is effective in treating diabetes. Risk of long-term complications reduced significantly.
    DukeMedicine healthnews, 2012, Volume: 18, Issue:9

    Topics: Blood Glucose; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypog

2012
Risk factors for intrahepatic cholangiocarcinoma: association between metformin use and reduced cancer risk.
    Hepatology (Baltimore, Md.), 2013, Volume: 57, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Case-Control Studies;

2013
Metformin inhibits glutaminase activity and protects against hepatic encephalopathy.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Age Factors; Ammonia; Diabetes Complications; Enzyme Inhibitors; Female; Glutaminase; Hepatic Enceph

2012
A nonhealing ulcer of mandibular alveolar ridge.
    Oral surgery, oral medicine, oral pathology and oral radiology, 2014, Volume: 117, Issue:3

    Topics: Alveolar Process; Antifungal Agents; Biopsy; Diabetes Complications; Diagnosis, Differential; Drug T

2014
Increased risk of affective disorders in type 2 diabetes is minimized by sulfonylurea and metformin combination: a population-based cohort study.
    BMC medicine, 2012, Nov-29, Volume: 10

    Topics: Adult; Aged; Aged, 80 and over; Cohort Studies; Comorbidity; Diabetes Complications; Diabetes Mellit

2012
Metformin intake is associated with better survival in ovarian cancer: a case-control study.
    Cancer, 2013, Feb-01, Volume: 119, Issue:3

    Topics: Aged; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Case-Control Studies; Cohort Studies; Di

2013
Diabetes medication use and blood lactate level among participants with type 2 diabetes: the atherosclerosis risk in communities carotid MRI study.
    PloS one, 2012, Volume: 7, Issue:12

    Topics: Aged; Aged, 80 and over; Atherosclerosis; Blood Glucose; Cohort Studies; Cross-Sectional Studies; Di

2012
[Metformin--sensible or nonsensible change of treatment in the post-operative phase].
    Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 2002, Volume: 37, Issue:8

    Topics: Acidosis, Lactic; Blood Glucose; Diabetes Complications; Humans; Hypoglycemic Agents; Metformin; Pos

2002
Therapeutic approach in insulin resistance with acanthosis nigricans.
    International journal of clinical practice, 2002, Volume: 56, Issue:8

    Topics: Acanthosis Nigricans; Adolescent; Adult; Body Mass Index; Body Weight; Diabetes Complications; Diabe

2002
Metformin-induced hemolytic anemia in a patient with glucose-6- phosphate dehydrogenase deficiency.
    Diabetes care, 2003, Volume: 26, Issue:3

    Topics: Aged; Anemia, Hemolytic; Diabetes Complications; Diabetes Mellitus; Female; Glucosephosphate Dehydro

2003
[Current methods of glucose metabolism control in diabetes mellitus].
    Recenti progressi in medicina, 2003, Volume: 94, Issue:1

    Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus

2003
[Metformin-associated lactic acidosis remains a serious complication of metformin therapy].
    Annales francaises d'anesthesie et de reanimation, 2003, Volume: 22, Issue:5

    Topics: Acidosis, Lactic; Acute Kidney Injury; Adult; Aged; Diabetes Complications; Diabetes Mellitus, Type

2003
Metformin and thiazolidinedione use in Medicare patients with heart failure.
    JAMA, 2003, Jul-02, Volume: 290, Issue:1

    Topics: Aged; Aged, 80 and over; Cardiotonic Agents; Contraindications; Cross-Sectional Studies; Diabetes Co

2003
Diabetes drugs a problem in heart failure.
    Harvard heart letter : from Harvard Medical School, 2003, Volume: 14, Issue:1

    Topics: Diabetes Complications; Diabetes Mellitus; Heart Failure; Humans; Hypoglycemic Agents; Metformin; Th

2003
The treatment of polycystic ovary syndrome.
    Minerva ginecologica, 2004, Volume: 56, Issue:1

    Topics: Adult; Androgen Antagonists; Cabergoline; Cardiovascular Diseases; Clomiphene; Cyproterone Acetate;

2004
Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention.
    The American journal of cardiology, 2004, Jun-01, Volume: 93, Issue:11

    Topics: Angioplasty, Balloon, Coronary; Case-Control Studies; Coronary Restenosis; Databases, Factual; Diabe

2004
Evidence based medicine, guidelines and common sense.
    Age and ageing, 2004, Volume: 33, Issue:4

    Topics: Aged; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; H

2004
Comparing the long-term cost-effectiveness of repaglinide plus metformin versus nateglinide plus metformin in type 2 diabetes patients with inadequate glycaemic control: an application of the CORE Diabetes Model in type 2 diabetes.
    Current medical research and opinion, 2004, Volume: 20 Suppl 1

    Topics: Carbamates; Cohort Studies; Computer Simulation; Cost of Illness; Cost-Benefit Analysis; Cyclohexane

2004
Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes.
    American heart journal, 2004, Volume: 148, Issue:6

    Topics: Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus; Drug Interactions; Humans; Hypog

2004
Determinants of subclinical diabetic heart disease.
    Diabetologia, 2005, Volume: 48, Issue:2

    Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Blood Glucose; Body Mass Index; Diabetes Complicati

2005
Metabolic syndrome: evaluation of pathological and therapeutic outcomes.
    American heart journal, 2005, Volume: 149, Issue:1

    Topics: Arteriosclerosis; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Complications; Endotheli

2005
AMPK activation as a strategy for reversing the endothelial lipotoxicity underlying the increased vascular risk associated with insulin resistance syndrome.
    Medical hypotheses, 2005, Volume: 64, Issue:6

    Topics: Adipocytes; Adiponectin; AMP-Activated Protein Kinases; Cardiovascular Diseases; Citrates; Diabetes

2005
Summaries for patients. The outcomes and costs of diabetes prevention with a diet and exercise program or metformin: a computer model.
    Annals of internal medicine, 2005, Aug-16, Volume: 143, Issue:4

    Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2

2005
Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes.
    Annals of internal medicine, 2005, Aug-16, Volume: 143, Issue:4

    Topics: Adult; Computer Simulation; Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2

2005
[Metformin-associated lactic acidosis in a patient with pre-existing risk factors].
    Praxis, 2005, Sep-07, Volume: 94, Issue:36

    Topics: Acidosis, Lactic; Acute Kidney Injury; Contraindications; Diabetes Complications; Diabetes Mellitus,

2005
Type 2 diabetes mellitus in youth: the complete picture to date.
    Pediatric clinics of North America, 2005, Volume: 52, Issue:6

    Topics: Adolescent; Autoantibodies; Child; Diabetes Complications; Diabetes Mellitus, Type 2; Diet; Dyslipid

2005
Sudden reversible osmotic lens damage ("sugar cracks") after initiation of metformin.
    The New England journal of medicine, 2005, Dec-15, Volume: 353, Issue:24

    Topics: Diabetes Complications; Diabetes Mellitus; Extracellular Fluid; Glucose; Humans; Hypoglycemic Agents

2005
Combined renal replacement therapy for severe metformin-induced lactic acidosis.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2006, Volume: 21, Issue:7

    Topics: Acidosis, Lactic; Aged; Diabetes Complications; Diabetes Mellitus, Type 2; Female; Hemofiltration; H

2006
[Glucose control in cardiac disease].
    Clinical research in cardiology : official journal of the German Cardiac Society, 2006, Volume: 95 Suppl 1

    Topics: Acarbose; Blood Glucose; Controlled Clinical Trials as Topic; Diabetes Complications; Glucose; Gluco

2006
Long-term efficacy of metformin therapy in nonobese individuals with type 2 diabetes.
    Diabetes care, 2006, Volume: 29, Issue:11

    Topics: Administration, Oral; Aged; Blood Glucose; Body Mass Index; Body Weight; Databases, Factual; Diabete

2006
Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study.
    Clinical therapeutics, 2007, Volume: 29, Issue:2

    Topics: Age Factors; Aged; Blood Glucose; Comorbidity; Databases, Factual; Diabetes Complications; Diabetes

2007
[No influence of imatinib on type 2 diabetes].
    Przeglad lekarski, 2007, Volume: 64, Issue:4-5

    Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Blood Glucose; Diabetes Complications; Diabetes Mell

2007
[Pioglitazone protects the type-2-diabetes patient from myocardial infarction and stroke].
    MMW Fortschritte der Medizin, 2007, Aug-02, Volume: 149, Issue:31-32

    Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Th

2007
Erythromelalgia in a diabetic patient managed with gabapentin.
    Diabetes research and clinical practice, 2008, Volume: 79, Issue:3

    Topics: Aged, 80 and over; Amines; Analgesics; Cyclohexanecarboxylic Acids; Diabetes Complications; Diabetes

2008
Cost-effectiveness analysis of thiazolidinediones in uncontrolled type 2 diabetic patients receiving sulfonylureas and metformin in Thailand.
    Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 2008, Volume: 11 Suppl 1

    Topics: Cost-Benefit Analysis; Diabetes Complications; Diabetes Mellitus, Type 2; Economics, Pharmaceutical;

2008
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
    Diabetes, obesity & metabolism, 2008, Volume: 10 Suppl 1

    Topics: Amputation, Surgical; Blindness; Cardiovascular Diseases; Computer Simulation; Diabetes Complication

2008
Metformin normalizes insulin binding to monocytes from obese nondiabetic subjects and obese type II diabetic patients.
    The Journal of clinical endocrinology and metabolism, 1983, Volume: 57, Issue:4

    Topics: Acetates; Adult; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Female; Humans; Insulin;

1983
[Reversible lactic acidosis in a diabetic on high dose metformin (author's transl)].
    Diabete & metabolisme, 1980, Volume: 6, Issue:3

    Topics: Adenoma; Diabetes Complications; Diabetes Mellitus; Diabetic Ketoacidosis; Humans; Lactates; Male; M

1980
Diabetes and bowel habits.
    The New England journal of medicine, 1983, May-19, Volume: 308, Issue:20

    Topics: Anal Canal; Diabetes Complications; Diabetes Mellitus; Diarrhea; Fecal Incontinence; Humans; Metform

1983
Arrhythmias and mortality after myocardial infarction in diabetic patients. Relationship to diabetes treatment.
    Diabetes care, 1998, Volume: 21, Issue:4

    Topics: Adult; Arrhythmias, Cardiac; Diabetes Complications; Diabetes Mellitus; Digitalis Glycosides; Diuret

1998
[Changes in clinical intervention studies: when the wellbeing of the patients takes precedence].
    Investigacion clinica, 1998, Volume: 39, Issue:3

    Topics: Antihypertensive Agents; Chromans; Clinical Trials as Topic; Diabetes Complications; Enalapril; Ethi

1998
Consequences of metformin intoxication.
    Diabetes care, 1998, Volume: 21, Issue:11

    Topics: Adolescent; Adult; Blood Glucose; Creatinine; Diabetes Complications; Diabetes Mellitus; Female; Hum

1998
Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome.
    Fertility and sterility, 2002, Volume: 77, Issue:3

    Topics: Adult; Blood Glucose; Body Weight; Cohort Studies; Diabetes Complications; Diabetes Mellitus; Diabet

2002
[Fatty liver and raised gamma-GT: it can happen to abstainers, too].
    MMW Fortschritte der Medizin, 2002, Feb-14, Volume: 144, Issue:7

    Topics: Cholagogues and Choleretics; Clinical Enzyme Tests; Diabetes Complications; Diagnosis, Differential;

2002
Implications of the United Kingdom Prospective Diabetes Study.
    Diabetes care, 2000, Volume: 23 Suppl 1

    Topics: Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Complications; Diabetes Mellitus; D

2000
Hypolipidemic effects of metformin in hyperprebetalipoproteinemia.
    Diabete & metabolisme, 1976, Volume: 2, Issue:3

    Topics: Adult; Blood Glucose; Body Weight; Cholesterol; Diabetes Complications; Female; Glucose Tolerance Te

1976
Hyperlipidaemia and treatment of diabetes.
    The Practitioner, 1979, Volume: 222, Issue:1327

    Topics: Aged; Cholesterol; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Male;

1979
Plasma renin activity in diabetes mellitus.
    Clinical science (London, England : 1979), 1979, Volume: 56, Issue:3

    Topics: Adult; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hypertension; Insulin; Male; Metfo

1979
Myocardial infarction in diabetics.
    The Quarterly journal of medicine, 1975, Volume: 44, Issue:173

    Topics: Administration, Oral; Adult; Aged; Chlorpropamide; Coronary Care Units; Diabetes Complications; Diab

1975
[Acute renal failure after intravenous urography in diabetics. Incidence of lactic acidosis in metformin treatment].
    Annales de medecine interne, 1977, Volume: 128, Issue:2

    Topics: Acidosis; Acute Kidney Injury; Aged; Contrast Media; Diabetes Complications; Diabetes Mellitus; Fema

1977
Letter: Coronary care for myocardial infarction in diabetics.
    Lancet (London, England), 1974, Jun-29, Volume: 1, Issue:7870

    Topics: Biguanides; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Diet Therapy; Humans;

1974
[Reversible hyperlactatemia induced by phenformin with muscular asthenia and cardio-respiratory signs].
    La Presse medicale, 1970, Jan-03, Volume: 78, Issue:1

    Topics: Aged; Animals; Asthenia; Diabetes Complications; Diabetic Ketoacidosis; Dyspnea; Heart Diseases; Hep

1970